{"id":"articaine","rwe":[],"_fda":{"id":"253a3ea1-c583-49d4-9655-b33ffa1115b0","set_id":"0536a4de-578d-497e-a01b-0b1887344cc8","openfda":{"unii":["30Q7KI53AK","QS9014Q792"],"route":["SUBMUCOSAL"],"rxcui":["1658966","1661483"],"spl_id":["253a3ea1-c583-49d4-9655-b33ffa1115b0"],"brand_name":["Articaine HCl and Epinephrine"],"spl_set_id":["0536a4de-578d-497e-a01b-0b1887344cc8"],"package_ndc":["67239-0209-1","67239-0210-1"],"product_ndc":["67239-0209","67239-0210"],"generic_name":["ARTICAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE"],"product_type":["HUMAN PRESCRIPTION DRUG"],"substance_name":["ARTICAINE HYDROCHLORIDE","EPINEPHRINE BITARTRATE"],"manufacturer_name":["Safco Dental Supply Co."],"application_number":["NDA022466"],"is_original_packager":[true]},"version":"7","pregnancy":["8.1 Pregnancy Teratogenic Effects-Pregnancy Category C. There are no adequate and well-controlled studies in pregnant women with articaine with epinephrine. Articaine hydrochloride and epinephrine (1:100,000) has been shown to increase fetal deaths and skeletal variations in rabbits when given in doses approximately 4 times the maximum recommended human dose (MRHD). Articaine HCl and Epinephrine should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. In embryo-fetal toxicity studies in rabbits, 80 mg/kg, subcutaneously (approximately 4 times the MRHD based on body surface area) caused fetal death and increased fetal skeletal variations, but these effects may be attributable to severe maternal toxicity, including seizures, observed at this dose. In contrast, no embryo-fetal toxicities were observed when articaine and epinephrine (1:100,000) was administered subcutaneously throughout organogenesis at doses up to 40 mg/kg in rabbits and 80 mg/kg in rats (approximately 2 times the MRHD based on body surface area). In pre- and postnatal developmental studies subcutaneous administration of articaine hydrochloride to pregnant rats throughout gestation and lactation, at a dose of 80 mg/kg (approximately 2 times the MRHD based on body surface area) increased the number of stillbirths and adversely affected passive avoidance, a measure of learning, in pups. This dose also produced severe maternal toxicity in some animals. A dose of 40 mg/kg (approximately equal to the MRHD on a mg/m2 basis) did not produce these effects. A similar study using articaine and epinephrine (1:100,000) rather than articaine hydrochloride alone produced maternal toxicity, but no effects on offspring."],"overdosage":["10 OVERDOSAGE Acute emergencies from local anesthetics are generally related to high plasma levels encountered during therapeutic use of local anesthetics or to unintended subarachnoid injection of local anesthetic solution [see Warnings and Precautions ( 5.1 , 5.2 )] . The first consideration is prevention, best accomplished by careful and constant monitoring of cardiovascular and respiratory vital signs and the patient’s state of consciousness after each local anesthetic injection. At the first sign of change, oxygen should be administered. The first step in the management of convulsions, as well as hypo-ventilation, consists of immediate attention to the maintenance of a patent airway and assisted or controlled ventilation as needed. The adequacy of the circulation should be assessed. Should convulsions persist despite adequate respiratory support, treatment with appropriate anticonvulsant therapy is indicated. The practitioner should be familiar with the use of anticonvulsant drugs, prior to the use of local anesthetics. Supportive treatment of circulatory depression may require administration of intravenous fluids and, when appropriate, a vasopressor. If not treated immediately, both convulsions and cardiovascular depression can result in hypoxia, acidosis, bradycardia, arrhythmias, and/or cardiac arrest. If cardiac arrest should occur, standard cardiopulmonary resuscitative measures should be instituted. For additional information about overdose treatment, call a poison control center (1-800-222-1222) ."],"references":["15 REFERENCES Kaplan, EL, editor. Cardiovascular disease in dental practice. Dallas; American Heart Association; 1986."],"description":["11 DESCRIPTION Articaine HCl and Epinephrine (articaine hydrochloride and epinephrine injection), for intraoral submucosal infiltration use, is a sterile, aqueous solution that contains articaine HCl 4% (40mg/mL) and epinephrine bitartrate in an epinephrine 1:200,000 or epinephrine 1:100,000 strength. Articaine HCl is an amino amide local anesthetic, chemically designated as 4-methyl-3-[2-(propylamino)- propionamido]-2-thiophene-carboxylic acid, methyl ester hydrochloride and is a racemic mixture. Articaine HCl has a molecular weight of 320.84 and the following structural formula: Articaine HCl has a partition coefficient in n-octanol/Soerensen buffer (pH 7.35) of 17 and a pKa of 7.8. Epinephrine bitartrate, (-)-1-(3,4-dihydroxyphenyl)-2-methylamino-ethanol (+) tartrate (1:1) salt, is a vasoconstrictor with a concentration of 1:200,000 or 1:100,000 (expressed as free base). It has a molecular weight of 333.3 and the following structural formula: Articaine HCl and Epinephrine contains the following inactive ingredients: sodium chloride (1.0 mg/mL), sodium metabisulfite (0.5 mg/mL), and water for injection. The product is formulated with a 10% overage of epinephrine. The pH is adjusted to 3.6 with hydrochloric acid. Articaine HCl structural formula Epinephrine bitartrate structural formula"],"how_supplied":["16 HOW SUPPLIED/STORAGE AND HANDLING Articaine HCl and Epinephrine (articaine hydrochloride and epinephrine) injection is a clear, colorless solution available in 1.8 mL single-dose glass cartridges, packaged in boxes of 50 and 100 cartridges in the following two strengths (less than a full cartridge or more than one cartridge may be used for an individual patient): Articaine HCl 4% (40 mg/mL) and epinephrine 1:200,000 (as epinephrine bitartrate 0.09 mg/mL): NDC 67239-0210-1 (50 cartridges/box) Articaine HCl 4% (40 mg/mL) and epinephrine 1:100,000 (as epinephrine bitartrate 0.018 mg/mL): NDC 67239-0209-1 (50 cartridges/box), Both products are formulated with a 10% overage of epinephrine. Storage and Handling Store at 20° to 25°C (68° to 77°F); excursions permitted between 15° to 30°C (59° to 86°F) [See USP Controlled Room Temperature]. Protect from light. Do not freeze."],"geriatric_use":["8.5 Geriatric Use In clinical trials, 54 patients between the ages of 65 and 75 years, and 11 patients 75 years and over received another product containing articaine and epinephrine 1:100,000. Among all patients between 65 and 75 years, doses from 0.43 mg/kg to 4.76 mg/kg (0.9 mL to 11.9 mL) of articaine HCl were administered safely to 35 patients for simple procedures and doses from 1.05 mg/kg to 4.27 mg/kg (1.3 mL to 6.8 mL) of articaine HCl were administered safely to 19 patients for complex procedures. Among the 11 patients ≥ 75 years old, doses from 0.78 mg/kg to 4.76 mg/kg (1.3 mL to 11.9 mL) of articaine HCl were administered safely to 7 patients for simple procedures and doses of 1.12 mg/kg to 2.17 mg/kg (1.3 mL to 5.1 mL) of articaine HCl were safely administered to 4 patients for complex procedures. Approximately 6% of patients between the ages of 65 and 75 years and none of the 11 patients 75 years of age or older required additional injections of anesthetic for complete anesthesia compared with 11% of patients between 17 and 65 years old who required additional injections. No overall differences in safety or effectiveness were observed between elderly subjects and younger subjects, and other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out."],"pediatric_use":["8.4 Pediatric Use Safety and effectiveness of Articaine HCl and Epinephrine in pediatric patients below the age of 4 years have not been established. Safety of doses greater than 7 mg/kg (0.175 mL/kg) in pediatric patients has not been established. The safety and effectiveness of Articaine HCl and Epinephrine for local, infiltrative, or conductive anesthesia in both simple and complex dental procedures have been established in pediatric patients ages 4 to 16 years old. Safety and effectiveness was established in clinical trials with 61 pediatric patients between the ages of 4 and 16 years administered another product containing articaine hydrochloride 4% and epinephrine 1:100,000 injections. Fifty-one of these patients received doses from 0.76 mg/kg to 5.65 mg/kg (0.9 mL to 5.1 mL) of articaine HCl for simple dental procedures and 10 patients received doses between 0.37 mg/kg and 7.48 mg/kg (0.7 mL to 3.9 mL) of articaine HCl for complex dental procedures. Approximately 13% of these pediatric patients required additional injections of anesthetic for complete anesthesia. Safety of doses greater than 7 mg/kg (0.175 mL/kg) of articaine HCl in pediatric patients has not been established. Dosages in pediatric patients should be reduced, commensurate with age, body weight, and physical condition [see Dosage and Administration ( 2.2 )] ."],"effective_time":"20230114","nursing_mothers":["8.3 Nursing Mothers It is not known whether Articaine HCl and Epinephrine is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when Articaine HCl and Epinephrine is administered to a nursing woman. When using Articaine HCl and Epinephrine, nursing mothers may choose to pump and discard breast milk for approximately 4 hours (based on plasma half-life) following an injection of Articaine HCl and Epinephrine (to minimize infant ingestion) and then resume breastfeeding."],"clinical_studies":["14 CLINICAL STUDIES Another product containing articaine with epinephrine 1:100,000 was studied in three randomized, double-blind, active-controlled trials to evaluate the effectiveness of articaine containing epinephrine 1:100,000 as a dental anesthetic. Patients ranging in age from 4 years to over 65 years old underwent simple dental procedures such as single uncomplicated extractions, routine operative procedures, single apical resections, and single crown procedures, or complex dental procedures such as multiple extractions, multiple crowns and/or bridge procedures, multiple apical resections, alveolectomies, muco-gingival operations, and other surgical procedures on the bone. Articaine containing epinephrine 1:100,000 was administered by intraoral submucosal infiltration for these dental procedures. Efficacy was measured immediately following the procedure by having the patient and investigator rate the patient’s procedural pain using a 10 cm visual analog scale (VAS), in which a score of zero represented no pain and a score of 10 represented the worst pain imaginable. Mean patient and investigator VAS pain scores were 0.3 cm-0.4 cm for simple procedures and 0.5 cm-0.6 cm for complex procedures. Articaine with epinephrine 1:100,000 was also studied compared to articaine with epinephrine 1:200,000 in four randomized, double-blind, active controlled trials. The first two studies used electric pulp testers (EPT) to evaluate the success rate (maximum EPT value within 10 minutes), onset, and duration of articaine containing epinephrine 1:100,000 versus articaine containing epinephrine 1:200,000 and articaine solution without epinephrine in healthy adults between 18 and 65 years old. Results indicated that the anesthetic characteristics of the 1:100,000 and 1:200,000 formulations were not significantly different. A third study compared the difference in visualization of the surgical field after administration of articaine containing 1:100,000 epinephrine versus articaine containing 1:200,000 epinephrine during bilateral maxillary periodontal surgeries in patients ranging from 21 to 65 years old. Articaine containing 1:100,000 epinephrine provided better visualization of the surgical field and less blood loss during the procedures. In a fourth study, designed to assess and compare cardiovascular safety, when the maximum dose of each formulation was administered, no clinically relevant differences in blood pressure or heart rate between formulations were observed."],"pharmacodynamics":["12.2 Pharmacodynamics Clinically, the order of loss of nerve function is as follows: (1) pain; (2) temperature; (3) touch; (4) proprioception; and (5) skeletal muscle tone. The onset of anesthesia has been shown to be within 1 to 9 minutes of injection of Articaine HCl and Epinephrine. Complete anesthesia lasts approximately 1 hour for infiltrations and up to approximately 2 hours for nerve block. Administration of Articaine HCl and Epinephrine results in a 3- to 5-fold increase in plasma epinephrine concentrations compared to baseline; however, in healthy adults it does not appear to be associated with marked increases in blood pressure or heart rate, except in the case of accidental intravascular injection [see Warnings and Precautions ( 5.1 )] ."],"pharmacokinetics":["12.3 Pharmacokinetics Absorption Following dental injection by the submucosal route of an articaine solution containing epinephrine 1:200,000, articaine reaches peak blood concentration about 25 minutes after a single dose injection and 48 minutes after three doses. Peak plasma levels of articaine achieved after 68 mg and 204 mg doses are 385 ng/mL and 900 ng/mL, respectively. Following intraoral administration of a near maximum dose of 476 mg, articaine reaches peak blood concentrations of 2037 ng/mL and 2145 ng/mL for articaine solution containing epinephrine 1:100,000 and 1:200,000, respectively, approximately 22 minutes post-dose. Distribution Approximately 60% to 80% of articaine HCl is bound to human serum albumin and γ -globulins at 37°C in vitro . Elimination Metabolism: Articaine HCl is metabolized by plasma carboxyesterase to its primary metabolite, articainic acid, which is inactive. In vitro studies show that the human liver microsome P450 isoenzyme system metabolizes approximately 5% to 10% of available articaine with nearly quantitative conversion to articainic acid. Excretion: At the dose of 476 mg of articaine, the elimination half-life was 43.8 minutes and 44.4 minutes for articaine solution containing epinephrine 1:100,000 and 1:200,000, respectively. Articaine is excreted primarily through urine with 53% to 57% of the administered dose eliminated in the first 24 hours following submucosal administration. Articainic acid is the primary metabolite in urine. A minor metabolite, articainic acid glucuronide, is also excreted in urine. Articaine constitutes only 2% of the total dose excreted in urine."],"adverse_reactions":["6 ADVERSE REACTIONS Reactions to articaine are characteristic of those associated with other amide local anesthetics. Adverse reactions to this group of drugs may also result from excessive plasma levels (which may be due to overdosage, unintentional intravascular injection, or slow metabolic degradation), injection technique, volume of injection, or hypersensitivity or they may be idiosyncratic. The most common adverse reactions (incidence >2%) are headache and pain ( 6.1 ). To report SUSPECTED ADVERSE REACTIONS, contact Pierrel S.p.A. at 610-989-4213 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Studies Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed cannot be directly compared to rates in other clinical trials and may not reflect the rates observed in practice. The reported adverse events are derived from clinical trials in the United States and the United Kingdom with a similar product containing articaine and epinephrine. Table 2 displays the adverse events reported in clinical trials where 882 individuals were exposed to articaine containing epinephrine 1:100,000. Table 3 displays the adverse events reported in clinical trials where 182 individuals were exposed to articaine containing epinephrine 1:100,000 and 179 individuals were exposed to articaine containing epinephrine 1:200,000. Adverse reactions observed in at least 1% of patients: Table 2: Adverse Reactions in Controlled Trials with an Incidence of 1% or Greater in Patients Administered articaine containing epinephrine 1:100,000 Body System/Reaction articaine containing epinephrine 1:100,000 (N=882) Incidence Body as a whole Face edema 13 (1%) Headache 31 (4%) Infection 10 (1%) Pain 114 (13%) Digestive system Gingivitis 13 (1%) Nervous system Paresthesia 11 (1%) Table 3: Adverse Reactions in Controlled Trials with an Incidence of 1% or Greater in Patients Administered articaine containing epinephrine 1:200,000 and articaine containing epinephrine 1:100,000 Reaction articaine with epinephrine 1:200,000 (N=179) Incidence articaine with epinephrine 1:100,000 (N=182) Incidence Any adverse event 33 (18%) 35 (19%) Pain 11 (6.1%) 14 (7.6%) Headache 9 (5%) 6 (3.2%) Positive blood aspiration into syringe 3 (1.6%) 6 (3.2%) Swelling 3 (1.6%) 5 (2.7%) Trismus 1 (0.3%) 3 (1.6%) Nausea and emesis 3 (1.6%) 0 (0%) Sleepiness 2 (1.1%) 1 (0.5%) Numbness and tingling 1 (0.5%) 2 (1.%) Palpitation 0 (0%) 2 (1.%) Ear symptoms (earache, otitis media) 1 (0.5%) 2 (1.%) Cough, persistent cough 0 (0%) 2 (1.%) Adverse reactions observed in less than 1% of patients: Table 4: Adverse Reactions in Controlled Trials with an Incidence of Less than 1% but Considered Clinically Relevant Body System Events Body as a Whole Asthenia; back pain; injection site pain; burning sensation above injection site; malaise; neck pain Cardiovascular System Hemorrhage; migraine; syncope; tachycardia; elevated blood pressure Digestive System Dyspepsia; glossitis; gum hemorrhage; mouth ulceration; nausea; stomatitis; tongue edemas; tooth disorder; vomiting Hemic and Lymphatic System Ecchymosis; lymphadenopathy Metabolic and Nutritional System Edema; thirst Musculoskeletal System Arthralgia; myalgia; osteomyelitis Nervous System Dizziness; dry mouth; facial paralysis; hyperesthesia; increased salivation; nervousness; neuropathy; paresthesia; somnolence; exacerbation of Kearns-Sayre Syndrome Respiratory System Pharyngitis; rhinitis; sinus pain; sinus congestion Skin and Appendages Pruritus; skin disorder Special Senses Ear pain; taste perversion 6.2 Postmarketing Experience The following adverse reactions have been identified during post-approval use of articaine hydrochloride with epinephrine. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Persistent paresthesias of the lips, tongue, and oral tissues have been reported with use of articaine hydrochloride, with slow, incomplete, or no recovery. These postmarketing events have been reported chiefly following nerve blocks in the mandible and have involved the trigeminal nerve and its branches. Hypoesthesia has been reported with use of articaine, especially in pediatric age groups, which is usually reversible. Prolonged numbness can result in soft tissue injuries such as that of the lips and tongue in these age groups. Ischemic injury and necrosis has been described following use of articaine with epinephrine and has been postulated to be due to vascular spasm of terminal arterial branches. Paralysis of ocular muscles has been reported, especially after posterior, superior alveolar injections of articaine during dental anesthesia. Symptoms include diplopia, mydriasis, ptosis and difficulty in abduction of the affected eye. These symptoms have been described as developing immediately after injection of the anesthetic solution and persisting one minute to several hours, with generally complete recovery."],"contraindications":["4 CONTRAINDICATIONS Articaine HCl and Epinephrine is contraindicated in patients who are hypersensitive to products containing sulfites. Products containing sulfites may cause allergic-type reactions including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in certain susceptible people. Sulfite sensitivity is seen more frequently in asthmatic than in non-asthmatic people [see Warnings and Precautions ( 5.5 )] . Known hypersensitivity to sulfite ( 4 )"],"drug_interactions":["7 DRUG INTERACTIONS The administration of local anesthetic solutions containing epinephrine to patients receiving monoamine oxidase inhibitors, nonselective beta-adrenergic antagonists or tricyclic antidepressants may produce severe, prolonged hypertension. Phenothiazines and butyrophenones may reduce or reverse the pressor effect of epinephrine. Concurrent use of these agents should generally be avoided. In situations when concurrent therapy is necessary, careful patient monitoring is essential [see Warnings and Precautions ( 5.1 )] . Patients who are administered local anesthetics are at increased risk of developing methemoglobinemia when concurrently exposed to the following drugs, which could include other local anesthetics: Table 5: Examples of Drugs Associated with Methemoglobinemia: Class Examples Nitrates/Nitrites nitric oxide, nitroglycerin, nitroprusside, nitrous oxide Local anesthetics articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, ropivacaine, procaine, tetracaine Antineoplastic agents cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase Antibiotics dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides Antimalarials chloroquine, primaquine Anticonvulsants phenobarbital, phenytoin, sodium valproate, Other drugs acetaminophen, metoclopramide, quinine, sulfasalazine Monoamine Oxidase Inhibitors, Nonselective Beta-adrenergic Antagonists, or Tricyclic Antidepressants : May produce severe, prolonged hypertension ( 7 ) Phenothiazines and butyrophenones : May reduce or reverse the pressor effect of epinephrine ( 7 )"],"mechanism_of_action":["12.1 Mechanism of Action Articaine HCl is an amide local anesthetic. Local anesthetics block the generation and conduction of nerve impulses, presumably by increasing the threshold for electrical excitation in the nerve, by slowing the propagation of the nerve impulse and by reducing the rate of rise of the action potential. In general, the progression of anesthesia is related to the diameter, myelination, and conduction velocity of the affected nerve fibers. Epinephrine is a vasoconstrictor added to articaine HCl to slow absorption into the general circulation and thus prolong maintenance of an active tissue concentration."],"recent_major_changes":["Warnings and Precautions, Methemoglobinemia ( 5.4 ) 11/2018"],"storage_and_handling":["Articaine HCl and Epinephrine (articaine hydrochloride and epinephrine) injection is a clear, colorless solution available in 1.8 mL single-dose glass cartridges, packaged in boxes of 50 and 100 cartridges in the following two strengths (less than a full cartridge or more than one cartridge may be used for an individual patient): Articaine HCl 4% (40 mg/mL) and epinephrine 1:200,000 (as epinephrine bitartrate 0.09 mg/mL): NDC 67239-0210-1 (50 cartridges/box) Articaine HCl 4% (40 mg/mL) and epinephrine 1:100,000 (as epinephrine bitartrate 0.018 mg/mL): NDC 67239-0209-1 (50 cartridges/box), Both products are formulated with a 10% overage of epinephrine. Storage and Handling Store at 20° to 25°C (68° to 77°F); excursions permitted between 15° to 30°C (59° to 86°F) [See USP Controlled Room Temperature]. Protect from light. Do not freeze."],"clinical_pharmacology":["12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Articaine HCl is an amide local anesthetic. Local anesthetics block the generation and conduction of nerve impulses, presumably by increasing the threshold for electrical excitation in the nerve, by slowing the propagation of the nerve impulse and by reducing the rate of rise of the action potential. In general, the progression of anesthesia is related to the diameter, myelination, and conduction velocity of the affected nerve fibers. Epinephrine is a vasoconstrictor added to articaine HCl to slow absorption into the general circulation and thus prolong maintenance of an active tissue concentration. 12.2 Pharmacodynamics Clinically, the order of loss of nerve function is as follows: (1) pain; (2) temperature; (3) touch; (4) proprioception; and (5) skeletal muscle tone. The onset of anesthesia has been shown to be within 1 to 9 minutes of injection of Articaine HCl and Epinephrine. Complete anesthesia lasts approximately 1 hour for infiltrations and up to approximately 2 hours for nerve block. Administration of Articaine HCl and Epinephrine results in a 3- to 5-fold increase in plasma epinephrine concentrations compared to baseline; however, in healthy adults it does not appear to be associated with marked increases in blood pressure or heart rate, except in the case of accidental intravascular injection [see Warnings and Precautions ( 5.1 )] . 12.3 Pharmacokinetics Absorption Following dental injection by the submucosal route of an articaine solution containing epinephrine 1:200,000, articaine reaches peak blood concentration about 25 minutes after a single dose injection and 48 minutes after three doses. Peak plasma levels of articaine achieved after 68 mg and 204 mg doses are 385 ng/mL and 900 ng/mL, respectively. Following intraoral administration of a near maximum dose of 476 mg, articaine reaches peak blood concentrations of 2037 ng/mL and 2145 ng/mL for articaine solution containing epinephrine 1:100,000 and 1:200,000, respectively, approximately 22 minutes post-dose. Distribution Approximately 60% to 80% of articaine HCl is bound to human serum albumin and γ -globulins at 37°C in vitro . Elimination Metabolism: Articaine HCl is metabolized by plasma carboxyesterase to its primary metabolite, articainic acid, which is inactive. In vitro studies show that the human liver microsome P450 isoenzyme system metabolizes approximately 5% to 10% of available articaine with nearly quantitative conversion to articainic acid. Excretion: At the dose of 476 mg of articaine, the elimination half-life was 43.8 minutes and 44.4 minutes for articaine solution containing epinephrine 1:100,000 and 1:200,000, respectively. Articaine is excreted primarily through urine with 53% to 57% of the administered dose eliminated in the first 24 hours following submucosal administration. Articainic acid is the primary metabolite in urine. A minor metabolite, articainic acid glucuronide, is also excreted in urine. Articaine constitutes only 2% of the total dose excreted in urine."],"indications_and_usage":["1 INDICATIONS AND USAGE Articaine HCl and Epinephrine is indicated for local, infiltrative, or conductive anesthesia in both simple and complex dental procedures in adults and pediatric patients 4 years of age and older. Articaine HCl and Epinephrine is a combination of articaine HCl, an amide local anesthetic, and epinephrine, a vasoconstrictor, indicated for local, infiltrative, or conductive anesthesia in both simple and complex dental procedures in adults and pediatric patients 4 years of age and older ( 1 )."],"warnings_and_cautions":["5 WARNINGS AND PRECAUTIONS Accidental Intravascular Injection: May be associated with convulsions followed by coma and respiratory arrest. Resuscitative equipment, oxygen and other resuscitative drugs should be available. ( 5.1 ) Systemic Toxicity: Systemic absorption of Articaine HCl and Epinephrine can produce effects on the central nervous and cardiovascular systems. ( 5.2 ) Vasoconstrictor Toxicity : Local anesthetic solutions like Articaine HCl and Epinephrine that contain a vasoconstrictor should be used cautiously, especially in patients with impaired cardiovascular function or vascular disease. ( 5.3 ) Methemoglobinemia: Cases of methemoglobinemia have been reported in association with local anesthetic use. ( 5.4 ) 5.1 Accidental Intravascular Injection Accidental intravascular injection of Articaine HCl and Epinephrine may be associated with convulsions, followed by central nervous system or cardiorespiratory depression and coma, progressing ultimately to respiratory arrest. Dental practitioners who employ local anesthetic agents including Articaine HCl and Epinephrine should be well versed in diagnosis and management of emergencies that may arise from their use. Resuscitative equipment, oxygen, and other resuscitative drugs should be available for immediate use. To avoid intravascular injection, aspiration should be performed before Articaine HCl and Epinephrine is injected. The needle must be repositioned until no return of blood can be elicited by aspiration. Note, however, that the absence of blood in the syringe does not guarantee that intravascular injection has been avoided. Small doses of local anesthetics injected in dental blocks may produce adverse reactions similar to systemic toxicity seen with unintentional intravascular injections of larger doses. Confusion, convulsions, respiratory depression and/or respiratory arrest, and cardiovascular stimulation or depression have been reported. These reactions may be due to intra-arterial injection of the local anesthetic with retrograde flow to the cerebral circulation. Patients receiving these blocks should be observed constantly. Resuscitative equipment and personnel for treating adverse reactions should be immediately available. Dosage recommendations should not be exceeded [see Dosage and Administration ( 2.1 )] . 5.2 Systemic Toxicity This includes toxicity arising from accidental intravascular injection of Articaine HCl and Epinephrine discussed in Section 5.1, as well as that related to higher systemic concentrations of local anesthetics or epinephrine [see Warnings and Precautions ( 5.3 )] . Systemic absorption of local anesthetics including Articaine HCl and Epinephrine can produce effects on the central nervous and cardiovascular systems. At blood concentrations achieved with therapeutic doses of Articaine HCl and Epinephrine, changes in cardiac conduction, excitability, refractoriness, contractility, and peripheral vascular resistance are minimal. However, toxic blood concentrations of Articaine HCl and Epinephrine can depress cardiac conduction and excitability, which may lead to atrioventricular block, ventricular arrhythmias, and cardiac arrest, possibly resulting in fatalities. In addition, myocardial contractility is depressed and peripheral vasodilatation occurs, leading to decreased cardiac output and arterial blood pressure. Articaine HCl and Epinephrine should also be used with caution in patients with heart block as well as those with impaired cardiovascular function since they may be less able to compensate for functional changes associated with the prolongation of A-V conduction produced by these drugs. Restlessness, anxiety, tinnitus, dizziness, blurred vision, tremors, depression, or drowsiness may be early warning signs of central nervous system toxicity. Careful and constant monitoring of cardiovascular and respiratory (adequacy of ventilation) vital signs and the patient’s state of consciousness should be performed after each local anesthetic injection of Articaine HCl and Epinephrine. Repeated doses of Articaine HCl and Epinephrine may cause significant increases in blood levels because of possible accumulation of the drug or its metabolites. The lowest dosage that results in effective anesthesia should be used to decrease the risk of high plasma levels and serious adverse effects. Tolerance to elevated blood levels varies with the status of the patient. Resuscitative equipment, oxygen, and other resuscitative drugs should be available for immediate use. Precautions for epinephrine administration, discussed in Section 5.3 should be observed. Debilitated patients, elderly patients, acutely ill patients, and pediatric patients should be given reduced doses commensurate with their age and physical condition [see Dosage and Administration ( 2.1 , 2.3 )] . No studies have been performed in patients with liver dysfunction, and caution should be used in patients with severe hepatic disease. 5.3 Vasoconstrictor Toxicity Articaine HCl and Epinephrine contains epinephrine, a vasoconstrictor that can cause local or systemic toxicity and should be used cautiously. Local toxicity may include ischemic injury or necrosis, which may be related to vascular spasm. Articaine HCl and Epinephrine should be used with caution in patients during or following the administration of potent general anesthetic agents, since cardiac arrhythmias may occur under such conditions. Patients with peripheral vascular disease and those with hypertensive vascular disease may exhibit exaggerated vasoconstrictor response. The American Heart Association has made the following recommendation regarding the use of local anesthetics with vasoconstrictors in patients with ischemic heart disease: “Vasoconstrictor agents should be used in local anesthesia solutions during dental practice only when it is clear that the procedure will be shortened or the analgesia rendered more profound. When a vasoconstrictor is indicated, extreme care should be taken to avoid intravascular injection. The minimum possible amount of vasoconstrictor should be used.” (Kaplan, 1986). It is essential to aspirate before any injection to avoid administration of the drug into the blood stream. 5.4 Methemoglobinemia Cases of methemoglobinemia have been reported in association with local anesthetic use. Although all patients are at risk for methemoglobinemia, patients with glucose-6-phosphate dehydrogenase deficiency, congenital or idiopathic methemoglobinemia, cardiac or pulmonary compromise, infants under 6 months of age, and concurrent exposure to oxidizing agents or their metabolites are more susceptible to developing clinical manifestations of the condition. If local anesthetics must be used in these patients, close monitoring for symptoms and signs of methemoglobinemia is recommended. Signs of methemoglobinemia may occur immediately or may be delayed some hours after exposure, and are characterized by a cyanotic skin discoloration and/or abnormal coloration of the blood. Methemoglobin levels may continue to rise; therefore, immediate treatment is required to avert more serious central nervous system and cardiovascular adverse effects, including seizures, coma, arrhythmias, and death. Discontinue Articaine HCl and Epinephrine and any other oxidizing agents. Depending on the severity of the signs and symptoms, patients may respond to supportive care, i.e., oxygen therapy, hydration. A more severe clinical presentation may require treatment with methylene blue, exchange transfusion, or hyperbaric oxygen. 5.5 Anaphylaxis and Allergic-Type Reactions Articaine HCl and Epinephrine contains sodium metabisulfite, a sulfite that may cause allergic-type reactions including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in certain susceptible people. The overall prevalence of sulfite sensitivity in the general population is unknown. Sulfite sensitivity is seen more frequently in asthmatic than in non-asthmatic people."],"nonclinical_toxicology":["13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility Studies to evaluate the carcinogenic potential of articaine HCI in animals have not been conducted. Five standard mutagenicity tests, including three in vitro tests (the nonmammalian Ames test, the mammalian Chinese hamster ovary chromosomal aberration test, and a mammalian gene mutation test with articaine HCl) and two in vivo mouse micronucleus tests (one with articaine and epinephrine 1:100,000 and one with articaine HCl alone) showed no mutagenic effects. No effects on male or female fertility were observed in rats for articaine and epinephrine 1:100,000 administered subcutaneously in doses up to 80 mg/kg/day (approximately 2 times the MRHD based on body surface area)."],"adverse_reactions_table":["
Table 2: Adverse Reactions in Controlled Trials with an Incidence of 1% or Greater in Patients Administered articaine containing epinephrine 1:100,000
Body System/Reactionarticaine containing epinephrine 1:100,000 (N=882) Incidence
Body as a whole
Face edema13 (1%)
Headache31 (4%)
Infection10 (1%)
Pain114 (13%)
Digestive system
Gingivitis13 (1%)
Nervous system
Paresthesia11 (1%)
","
Table 3: Adverse Reactions in Controlled Trials with an Incidence of 1% or Greater in Patients Administered articaine containing epinephrine 1:200,000 and articaine containing epinephrine 1:100,000
Reactionarticaine with epinephrine 1:200,000 (N=179) Incidencearticaine with epinephrine 1:100,000 (N=182) Incidence
Any adverse event33 (18%)35 (19%)
Pain11 (6.1%)14 (7.6%)
Headache9 (5%)6 (3.2%)
Positive blood aspiration into syringe3 (1.6%)6 (3.2%)
Swelling3 (1.6%)5 (2.7%)
Trismus1 (0.3%)3 (1.6%)
Nausea and emesis3 (1.6%)0 (0%)
Sleepiness2 (1.1%)1 (0.5%)
Numbness and tingling1 (0.5%)2 (1.%)
Palpitation0 (0%)2 (1.%)
Ear symptoms (earache, otitis media)1 (0.5%)2 (1.%)
Cough, persistent cough0 (0%)2 (1.%)
","
Table 4: Adverse Reactions in Controlled Trials with an Incidence of Less than 1% but Considered Clinically Relevant
Body SystemEvents
Body as a WholeAsthenia; back pain; injection site pain; burning sensation above injection site; malaise; neck pain
Cardiovascular SystemHemorrhage; migraine; syncope; tachycardia; elevated blood pressure
Digestive SystemDyspepsia; glossitis; gum hemorrhage; mouth ulceration; nausea; stomatitis; tongue edemas; tooth disorder; vomiting
Hemic and Lymphatic SystemEcchymosis; lymphadenopathy
Metabolic and Nutritional SystemEdema; thirst
Musculoskeletal SystemArthralgia; myalgia; osteomyelitis
Nervous SystemDizziness; dry mouth; facial paralysis; hyperesthesia; increased salivation; nervousness; neuropathy; paresthesia; somnolence; exacerbation of Kearns-Sayre Syndrome
Respiratory SystemPharyngitis; rhinitis; sinus pain; sinus congestion
Skin and AppendagesPruritus; skin disorder
Special SensesEar pain; taste perversion
"],"drug_interactions_table":["
Table 5: Examples of Drugs Associated with Methemoglobinemia:
ClassExamples
Nitrates/Nitritesnitric oxide, nitroglycerin, nitroprusside, nitrous oxide
Local anestheticsarticaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, ropivacaine, procaine, tetracaine
Antineoplastic agentscyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase
Antibioticsdapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides
Antimalarialschloroquine, primaquine
Anticonvulsantsphenobarbital, phenytoin, sodium valproate,
Other drugsacetaminophen, metoclopramide, quinine, sulfasalazine
"],"information_for_patients":["17 PATIENT COUNSELING INFORMATION Loss of Sensation and Muscle Function Inform patients in advance of the possibility of temporary loss of sensation and muscle function following infiltration and nerve block injections [see Adverse Reactions ( 6.2 )] . Instruct patients not to eat or drink until normal sensation returns. Methemoglobinemia • Inform patients that use of local anesthetics may cause methemoglobinemia, a serious condition that must be treated promptly. Advise patients or caregivers to seek immediate medical attention if they or someone in their care experience the following signs or symptoms: pale, gray, or blue colored skin (cyanosis); headache; rapid heart rate; shortness of breath; lightheadedness; or fatigue. Manufactured in Italy by: Pierrel S.p.A. - Strada Statale Appia 46/48 - 81043 Capua (CE), Italy Revised: 01/2023 00756637-01"],"dosage_and_administration":["2 DOSAGE AND ADMINISTRATION For dental procedures by intraoral submucosal infiltration or nerve block ( 2.1 ): For infiltration: 0.5 mL-2.5 mL (20 mg-100 mg articaine HCl) ( 2.1 ) For nerve block: 0.5 mL-3.4 mL (20 mg-136 mg articaine HCl) ( 2.1 ) For oral surgery: 1 ml-5.1 mL (40 mg-204 mg articaine HCl) ( 2.1 ) For most routine dental procedures, Articaine HCl and Epinephrine containing epinephrine 1:200,000 is preferred. However, when more pronounced homeostasis or improved visualization of the surgical field are required, Articaine HCl and Epinephrine containing epinephrine 1:100,000 may be used. ( 2.1 ) Maximum recommended dosages ( 2.2 ): Healthy adults: 7 mg/kg of articaine HCl and 0.0017mg/kg of epinephrine (equivalent to 0.175 mL/kg for either product presentation, articaine HCl and epinephrine 1:100,000 or 1:200,000) Pediatric patients 4-16 years: 7 mg/kg of articaine HCl and 0.0017mg/kg of epinephrine (equivalent to 0.175 mL/kg for either product presentation, articaine HCl and epinephrine 1:100,000 or 1:200,000) 2.1 General Dosing Information Table 1 summarizes the recommended dosages of Articaine HCl and Epinephrine administered by intraoral submucosal infiltration or nerve block for various types of anesthetic dental procedures in healthy adults and pediatric patients. Table 1: Recommended Dosages for Both Strengths Procedure Articaine HCl and Epinephrine Injection Volume (mL) Total dose of articaine HCl (mg) Infiltration 0.5 mL to 2.5 mL 20 mg to 100 mg Nerve block 0.5 mL to 3.4 mL 20 mg to 136 mg Oral surgery 1 mL to 5.1 mL 40 mg to 204 mg The recommended dosages of Articaine HCl and Epinephrine in healthy adults serve only as a guide to the amount of anesthetic required for most routine dental procedures. The dosage to be used in adults depend on several factors such as type and extent of surgical procedure, depth of anesthesia, degree of muscular relaxation, and condition of the patient. In all cases, administer the lowest dosage that will produce the desired result. The dosages of Articaine HCl and Epinephrine to be used in pediatric patients aged 4 to 16 years old are determined by the age and weight of the patient and the type of dental procedure. For most routine dental procedures, Articaine HCl and Epinephrine containing epinephrine 1:200,000 is preferred. However, when more pronounced hemostasis or improved visualization of the surgical field are required, Articaine HCl and Epinephrine containing epinephrine 1:100,000 may be used. The onset of anesthesia and the duration of anesthesia are proportional to the dosage of the local anesthetic used. Exercise caution when employing large volumes because the incidence of adverse reactions may be dose-related. 2.2 Maximum Recommended Dosages Healthy Adults : The maximum dosage of Articaine HCl and Epinephrine is 7 mg/kg of articaine and 0.0017mg/kg of epinephrine (equivalent to 0.175 mL/kg for either product presentation, articaine HCl and 1:100,000 or 1:200,000 epinephrine). Pediatric Patients Ages 4 to 16 Years : The maximum dosage of Articaine HCl and Epinephrine is 7 mg/kg of articaine and 0.0017mg/kg of epinephrine (equivalent to 0.175 mL/kg for either product presentation, articaine HCl and 1:100,000 or 1:200,000 epinephrine) [see Use in Specific Populations ( 8.4 )]. 2.3 Dosing in Special Populations Lower dosages or dosage reduction may be required in debilitated patients, acutely ill patients, elderly patients, and pediatric patients commensurate with their age and physical condition. No studies have been performed in patients with renal or liver impairment. Exercise caution when using Articaine HCl and Epinephrine in patients with severe liver disease. [see Warnings and Precautions ( 5.2 ), Use in Specific Populations ( 8.4 , 8.5 , and 8.6 )] 2.4 Important Administration Instructions Visually inspect Articaine HCl and Epinephrine for particulate matter and discoloration prior to administration. Articaine HCl and Epinephrine (articaine HCl and epinephrine) Injection is available in glass cartridges. Prior to using the glass cartridges, disinfect by wiping the cap thoroughly with USP isopropyl alcohol (70%). Avoid use of isopropyl alcohol, as well as solutions of ethyl alcohol that are not of USP grade because they may contain denaturants that are injurious to rubber. Immersion is not recommended."],"spl_product_data_elements":["Articaine HCl and Epinephrine articaine hydrochloride and epinephrine bitartrate ARTICAINE HYDROCHLORIDE ARTICAINE EPINEPHRINE BITARTRATE EPINEPHRINE Articaine HCl and Epinephrine articaine hydrochloride and epinephrine bitartrate ARTICAINE HYDROCHLORIDE ARTICAINE EPINEPHRINE BITARTRATE EPINEPHRINE"],"dosage_forms_and_strengths":["3 DOSAGE FORMS AND STRENGTHS Injection (clear colorless solution), provided in glass cartridges (single-dose) containing (less than a full cartridge or more than one cartridge can be used for an individual patient): Articaine hydrochloride 4% (40 mg/mL) and epinephrine 1:200,000 (as epinephrine bitartrate 0.009 mg/mL) Articaine hydrochloride 4% (40 mg/mL) and epinephrine 1:100,000 (as epinephrine bitartrate 0.018 mg/mL) Injection provided in glass cartridges (single-dose) containing: Articaine hydrochloride 4% (40 mg/mL) and epinephrine 1:200,000 (as epinephrine bitartrate 0.009 mg/mL) ( 3 ) Articaine hydrochloride 4% (40 mg/mL) and epinephrine 1:100,000 (as epinephrine bitartrate 0.018 mg/mL) ( 3 )"],"use_in_specific_populations":["8 USE IN SPECIFIC POPULATIONS Pregnancy: Based on animal studies, may cause fetal harm ( 8.1 ) Nursing Mothers: Exercise caution when administering to a nursing woman ( 8.3 ) Pediatric Use: Safety and effectiveness in pediatric patients below the age of 4 years have not been established ( 8.4 ) 8.1 Pregnancy Teratogenic Effects-Pregnancy Category C. There are no adequate and well-controlled studies in pregnant women with articaine with epinephrine. Articaine hydrochloride and epinephrine (1:100,000) has been shown to increase fetal deaths and skeletal variations in rabbits when given in doses approximately 4 times the maximum recommended human dose (MRHD). Articaine HCl and Epinephrine should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. In embryo-fetal toxicity studies in rabbits, 80 mg/kg, subcutaneously (approximately 4 times the MRHD based on body surface area) caused fetal death and increased fetal skeletal variations, but these effects may be attributable to severe maternal toxicity, including seizures, observed at this dose. In contrast, no embryo-fetal toxicities were observed when articaine and epinephrine (1:100,000) was administered subcutaneously throughout organogenesis at doses up to 40 mg/kg in rabbits and 80 mg/kg in rats (approximately 2 times the MRHD based on body surface area). In pre- and postnatal developmental studies subcutaneous administration of articaine hydrochloride to pregnant rats throughout gestation and lactation, at a dose of 80 mg/kg (approximately 2 times the MRHD based on body surface area) increased the number of stillbirths and adversely affected passive avoidance, a measure of learning, in pups. This dose also produced severe maternal toxicity in some animals. A dose of 40 mg/kg (approximately equal to the MRHD on a mg/m2 basis) did not produce these effects. A similar study using articaine and epinephrine (1:100,000) rather than articaine hydrochloride alone produced maternal toxicity, but no effects on offspring. 8.3 Nursing Mothers It is not known whether Articaine HCl and Epinephrine is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when Articaine HCl and Epinephrine is administered to a nursing woman. When using Articaine HCl and Epinephrine, nursing mothers may choose to pump and discard breast milk for approximately 4 hours (based on plasma half-life) following an injection of Articaine HCl and Epinephrine (to minimize infant ingestion) and then resume breastfeeding. 8.4 Pediatric Use Safety and effectiveness of Articaine HCl and Epinephrine in pediatric patients below the age of 4 years have not been established. Safety of doses greater than 7 mg/kg (0.175 mL/kg) in pediatric patients has not been established. The safety and effectiveness of Articaine HCl and Epinephrine for local, infiltrative, or conductive anesthesia in both simple and complex dental procedures have been established in pediatric patients ages 4 to 16 years old. Safety and effectiveness was established in clinical trials with 61 pediatric patients between the ages of 4 and 16 years administered another product containing articaine hydrochloride 4% and epinephrine 1:100,000 injections. Fifty-one of these patients received doses from 0.76 mg/kg to 5.65 mg/kg (0.9 mL to 5.1 mL) of articaine HCl for simple dental procedures and 10 patients received doses between 0.37 mg/kg and 7.48 mg/kg (0.7 mL to 3.9 mL) of articaine HCl for complex dental procedures. Approximately 13% of these pediatric patients required additional injections of anesthetic for complete anesthesia. Safety of doses greater than 7 mg/kg (0.175 mL/kg) of articaine HCl in pediatric patients has not been established. Dosages in pediatric patients should be reduced, commensurate with age, body weight, and physical condition [see Dosage and Administration ( 2.2 )] . 8.5 Geriatric Use In clinical trials, 54 patients between the ages of 65 and 75 years, and 11 patients 75 years and over received another product containing articaine and epinephrine 1:100,000. Among all patients between 65 and 75 years, doses from 0.43 mg/kg to 4.76 mg/kg (0.9 mL to 11.9 mL) of articaine HCl were administered safely to 35 patients for simple procedures and doses from 1.05 mg/kg to 4.27 mg/kg (1.3 mL to 6.8 mL) of articaine HCl were administered safely to 19 patients for complex procedures. Among the 11 patients ≥ 75 years old, doses from 0.78 mg/kg to 4.76 mg/kg (1.3 mL to 11.9 mL) of articaine HCl were administered safely to 7 patients for simple procedures and doses of 1.12 mg/kg to 2.17 mg/kg (1.3 mL to 5.1 mL) of articaine HCl were safely administered to 4 patients for complex procedures. Approximately 6% of patients between the ages of 65 and 75 years and none of the 11 patients 75 years of age or older required additional injections of anesthetic for complete anesthesia compared with 11% of patients between 17 and 65 years old who required additional injections. No overall differences in safety or effectiveness were observed between elderly subjects and younger subjects, and other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out. 8.6 Renal and Hepatic Impairment No studies have been performed with articaine hydrochloride 4% and epinephrine 1:200,000 injection or articaine hydrochloride 4% and epinephrine 1:100,000 injection in patients with renal or hepatic dysfunction [see Warnings and Precautions ( 5.2 )] ."],"dosage_and_administration_table":["
Table 1: Recommended Dosages for Both Strengths
ProcedureArticaine HCl and Epinephrine InjectionVolume (mL)Total dose of articaine HCl (mg)
Infiltration0.5 mL to 2.5 mL20 mg to 100 mg
Nerve block0.5 mL to 3.4 mL20 mg to 136 mg
Oral surgery1 mL to 5.1 mL40 mg to 204 mg
"],"package_label_principal_display_panel":["Package Label - Principal Display Panel – Articaine HCl and Epinephrine (Articaine Hydrochloride 4% and Epinephrine 1:100,000) Injection Cartridge Label Principal Display Panel – Articaine HCl and Epinephrine (Articaine Hydrochloride 4% and Epinephrine 1:100,000) Injection Cartridge Label","Package Label - Principal Display Panel – Articaine HCl and Epinephrine (Articaine Hydrochloride 4% and Epinephrine 1:100,000) Injection Carton Label Principal Display Panel – Articaine HCl and Epinephrine (Articaine Hydrochloride 4% and Epinephrine 1:100,000) Injection Cartron Label","Package Label - Principal Display Panel – Articaine HCl and Epinephrine (Articaine Hydrochloride 4% and Epinephrine 1:200,000) Injection Cartridge Label Principal Display Panel – Articaine HCl and Epinephrine (Articaine Hydrochloride 4% and Epinephrine 1:200,000) Injection Cartridge Label","Package Label - Principal Display Panel – Articaine HCl and Epinephrine (Articaine Hydrochloride 4% and Epinephrine 1:200,000) Injection Carton Label Principal Display Panel – Articaine HCl and Epinephrine (Articaine Hydrochloride 4% and Epinephrine 1:200,000) Injection Cartron Label"],"carcinogenesis_and_mutagenesis_and_impairment_of_fertility":["13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility Studies to evaluate the carcinogenic potential of articaine HCI in animals have not been conducted. Five standard mutagenicity tests, including three in vitro tests (the nonmammalian Ames test, the mammalian Chinese hamster ovary chromosomal aberration test, and a mammalian gene mutation test with articaine HCl) and two in vivo mouse micronucleus tests (one with articaine and epinephrine 1:100,000 and one with articaine HCl alone) showed no mutagenic effects. No effects on male or female fertility were observed in rats for articaine and epinephrine 1:100,000 administered subcutaneously in doses up to 80 mg/kg/day (approximately 2 times the MRHD based on body surface area)."]},"tags":[{"label":"Amide Local Anesthetic","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Sodium channel alpha subunits; brain (Types I, II, III)","category":"target"},{"label":"SCN1A","category":"gene"},{"label":"SCN2A","category":"gene"},{"label":"SCN3A","category":"gene"},{"label":"N01BB08","category":"atc"},{"label":"Submucosal","category":"route"},{"label":"Subcutaneous","category":"route"},{"label":"Injection","category":"form"},{"label":"Active","category":"status"},{"label":"Administration of Local Anesthetic Nerve Block","category":"indication"},{"label":"Local anesthesia, by infiltration","category":"indication"},{"label":"Approved 2000s","category":"decade"},{"label":"Anesthetics","category":"pharmacology"},{"label":"Anesthetics, Local","category":"pharmacology"},{"label":"Central Nervous System Agents","category":"pharmacology"},{"label":"Central Nervous System Depressants","category":"pharmacology"},{"label":"Peripheral Nervous System Agents","category":"pharmacology"},{"label":"Sensory System Agents","category":"pharmacology"}],"phase":"marketed","safety":{"boxedWarnings":[],"safetySignals":[{"date":"","signal":"DRUG INEFFECTIVE","source":"FDA FAERS","actionTaken":"319 reports"},{"date":"","signal":"HYPOAESTHESIA","source":"FDA FAERS","actionTaken":"43 reports"},{"date":"","signal":"HYPOAESTHESIA ORAL","source":"FDA FAERS","actionTaken":"41 reports"},{"date":"","signal":"DYSPNOEA","source":"FDA FAERS","actionTaken":"33 reports"},{"date":"","signal":"NAUSEA","source":"FDA FAERS","actionTaken":"29 reports"},{"date":"","signal":"PARAESTHESIA","source":"FDA FAERS","actionTaken":"28 reports"},{"date":"","signal":"HYPERSENSITIVITY","source":"FDA FAERS","actionTaken":"26 reports"},{"date":"","signal":"ANAPHYLACTIC REACTION","source":"FDA FAERS","actionTaken":"25 reports"},{"date":"","signal":"DIZZINESS","source":"FDA FAERS","actionTaken":"25 reports"},{"date":"","signal":"PAIN","source":"FDA FAERS","actionTaken":"24 reports"}],"drugInteractions":[{"drug":"monoamine oxidase inhibitors","severity":"major","mechanism":"interaction with epinephrine in local anesthetic solutions","management":"concurrent use should generally be avoided; if necessary, careful patient monitoring is essential","clinicalEffect":"severe, prolonged hypertension"},{"drug":"nonselective beta-adrenergic antagonists","severity":"major","mechanism":"interaction with epinephrine in local anesthetic solutions","management":"concurrent use should generally be avoided; if necessary, careful patient monitoring is essential","clinicalEffect":"severe, prolonged hypertension"},{"drug":"tricyclic antidepressants","severity":"major","mechanism":"interaction with epinephrine in local anesthetic solutions","management":"concurrent use should generally be avoided; if necessary, careful patient monitoring is essential","clinicalEffect":"severe, prolonged hypertension"},{"drug":"phenothiazines","severity":"moderate","mechanism":"interaction with epinephrine in local anesthetic solutions","management":"concurrent use should generally be avoided; if necessary, careful patient monitoring is essential","clinicalEffect":"may reduce or reverse the pressor effect of epinephrine"},{"drug":"butyrophenones","severity":"moderate","mechanism":"interaction with epinephrine in local anesthetic solutions","management":"concurrent use should generally be avoided; if necessary, careful patient monitoring is essential","clinicalEffect":"may reduce or reverse the pressor effect of epinephrine"},{"drug":"nitrates/nitrites (e.g., nitric oxide, nitroglycerin, nitroprusside, nitrous oxide)","severity":"moderate","mechanism":"concurrent exposure with local anesthetics","management":"monitor for signs of methemoglobinemia","clinicalEffect":"increased risk of developing methemoglobinemia"},{"drug":"local anesthetics (e.g., articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, ropivacaine, procaine, tetracaine)","severity":"moderate","mechanism":"concurrent exposure with other methemoglobinemia-inducing drugs","management":"monitor for signs of methemoglobinemia","clinicalEffect":"increased risk of developing methemoglobinemia"},{"drug":"antineoplastic agents (e.g., cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase)","severity":"moderate","mechanism":"concurrent exposure with local anesthetics","management":"monitor for signs of methemoglobinemia","clinicalEffect":"increased risk of developing methemoglobinemia"},{"drug":"antibiotics (e.g., dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides)","severity":"moderate","mechanism":"concurrent exposure with local anesthetics","management":"monitor for signs of methemoglobinemia","clinicalEffect":"increased risk of developing methemoglobinemia"},{"drug":"antimalarials (e.g., chloroquine, primaquine)","severity":"moderate","mechanism":"concurrent exposure with local anesthetics","management":"monitor for signs of methemoglobinemia","clinicalEffect":"increased risk of developing methemoglobinemia"},{"drug":"anticonvulsants (e.g., phenobarbital, phenytoin, sodium valproate)","severity":"moderate","mechanism":"concurrent exposure with local anesthetics","management":"monitor for signs of methemoglobinemia","clinicalEffect":"increased risk of developing methemoglobinemia"},{"drug":"other drugs (e.g., acetaminophen, metoclopramide, quinine, sulfasalazine)","severity":"moderate","mechanism":"concurrent exposure with local anesthetics","management":"monitor for signs of methemoglobinemia","clinicalEffect":"increased risk of developing methemoglobinemia"}],"commonSideEffects":[{"effect":"Face edema","drugRate":"1%","_validated":true,"placeboRate":""},{"effect":"Headache","drugRate":"4%","_validated":true,"placeboRate":""},{"effect":"Infection","drugRate":"1%","_validated":true,"placeboRate":""},{"effect":"Pain","drugRate":"13%","_validated":true,"placeboRate":""},{"effect":"Gingivitis","drugRate":"1%","_validated":true,"placeboRate":""},{"effect":"Paresthesia","drugRate":"1%","_validated":true,"placeboRate":""},{"effect":"Any adverse event","drugRate":"18%","_validated":true,"placeboRate":"19%"},{"effect":"Pain","drugRate":"6.1%","_validated":true,"placeboRate":"7.6%"},{"effect":"Headache","drugRate":"5%","_validated":true,"placeboRate":"3.2%"},{"effect":"Positive blood aspiration into syringe","drugRate":"1.6%","_validated":true,"placeboRate":"3.2%"},{"effect":"Swelling","drugRate":"1.6%","_validated":true,"placeboRate":"2.7%"},{"effect":"Trismus","drugRate":"0.3%","_validated":true,"placeboRate":"1.6%"},{"effect":"Nausea and emesis","drugRate":"1.6%","_validated":true,"placeboRate":"0%"},{"effect":"Sleepiness","drugRate":"1.1%","_validated":true,"placeboRate":"0.5%"},{"effect":"Numbness and tingling","drugRate":"0.5%","_validated":true,"placeboRate":"1.%"},{"effect":"Palpitation","drugRate":"0%","_validated":true,"placeboRate":"1.%"},{"effect":"Ear symptoms (earache, otitis media)","drugRate":"0.5%","_validated":true,"placeboRate":"1.%"},{"effect":"Cough, persistent cough","drugRate":"0%","_validated":true,"placeboRate":"1.%"}],"contraindications":["Articaine HCl and Epinephrine is contraindicated in patients who are hypersensitive to products containing sulfites.","Known hypersensitivity to sulfite."],"specialPopulations":{"Pregnancy":"Based on animal studies, may cause fetal harm. Use during pregnancy only if the potential benefit justifies the potential risk to the fetus. Teratogenic Effects-Pregnancy Category C. There are no adequate and well-controlled studies in pregnant women with articaine with epinephrine. Articaine hydrochloride and epinephrine (1:100,000) has been shown to increase fetal deaths and skeletal variations in rabbits when given in doses approximately 2 times the maximum recommended human dose (MRHD).","Geriatric use":"In clinical trials, 54 patients between the ages of 65 and 75 years, and 11 patients 75 years and over received Zorcaine containing epinephrine 1:100,000. Among all patients between 65 and 75 years, doses from 0.43 mg/kg to 4.76 mg/kg (0.9 to 11.9 mL) were administered to 35 patients for simple procedures and doses from 1.05 mg/kg to 4.27 mg/kg (1.3 to 6.8 mL) were administered to 19 patients for complex procedures. Among the 11 patients >= 75 years old, doses from 0.78 mg/kg to 3.45 mg/kg (0.9 to 4.8 mL) were administered.","Paediatric use":"Safety and effectiveness in pediatric patients below the age of 12 years have not been established. Safety of doses greater than 0.175 mL/kg in pediatric patients has not been established. Safety and effectiveness was established in clinical trials with 61 pediatric patients between the ages of 12 and 16 years administered articaine hydrochloride 4% and epinephrine 1:100,000 injections."}},"trials":[],"aliases":[],"patents":[{"applNo":"N218643","source":"FDA Orange Book","status":"Active","expires":"Mar 27, 2039","useCode":"U-4422","territory":"US","drugProduct":true,"patentNumber":"12403126","drugSubstance":false},{"applNo":"N218643","source":"FDA Orange Book","status":"Active","expires":"Mar 27, 2039","useCode":"U-4423","territory":"US","drugProduct":true,"patentNumber":"11826347","drugSubstance":false},{"applNo":"N218643","source":"FDA Orange Book","status":"Active","expires":"Mar 27, 2039","useCode":"U-4423","territory":"US","drugProduct":true,"patentNumber":"11096922","drugSubstance":false}],"pricing":[],"_fixedAt":"2026-03-30T16:19:58.413177","_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=ARTICAINE","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-19T23:36:16.305612+00:00"},"patents":{"url":"","method":"deterministic","source":"FDA Orange Book","rawText":"","confidence":1,"sourceType":"fda_orange_book","retrievedAt":"2026-04-19T23:36:16.305514+00:00"},"aiSummary":{"url":"","method":"ai_extraction","source":"AI Strategic Summary","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"ai_extraction","retrievedAt":"2026-04-19T23:38:28.535625+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-19T23:36:22.578794+00:00"},"regulatory.us":{"url":"","method":"api_direct","source":"FDA Drugs@FDA","rawText":"","confidence":1,"sourceType":"fda_drugsfda","retrievedAt":"2026-04-19T23:36:15.179345+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=ARTICAINE","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-19T23:36:22.912376+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-19T23:36:13.051127+00:00"},"indications.approved":{"url":"","method":"ai_extraction","source":"FDA Label + AI","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"fda_label","retrievedAt":"2026-04-19T23:38:21.920361+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (no boxed warning)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-19T23:36:13.051154+00:00"},"safety.safetySignals":{"url":"https://api.fda.gov/drug/event.json","method":"api_direct","source":"FDA FAERS","rawText":"","confidence":1,"sourceType":"fda_faers","retrievedAt":"2026-04-19T23:36:24.371181+00:00"},"mechanism.oneSentence":{"url":"","method":"ai_extraction","source":"FDA Label + AI","aiModel":"featherless","rawText":"12.1 Mechanism of Action Articaine HCl is an amide local anesthetic. Local anesthetics block the generation and conduction of nerve impulses, presumably by increasing the threshold for electrical excitation in the nerve, by slowing the propagation of the nerve impulse and by reducing the rate of rise of the action potential. In general, the progression of anesthesia is related to the diameter, myelination, and conduction velocity of the affected nerve fibers. Epinephrine is a vasoconstrictor add","confidence":0.95,"sourceType":"fda_label","retrievedAt":"2026-04-19T23:36:37.889764+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Sodium channel alpha subunit blocker","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-19T23:36:23.972921+00:00"},"safety.drugInteractions":{"url":"","method":"ai_extraction","source":"FDA Label + AI","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"fda_label","retrievedAt":"2026-04-19T23:38:15.278121+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1200819/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-19T23:36:23.621580+00:00"},"safety.commonSideEffects":{"url":"","method":"ai_extraction","source":"FDA Label + AI","aiModel":"featherless","rawText":"6 ADVERSE REACTIONS Reactions to articaine are characteristic of those associated with other amide local anesthetics. Adverse reactions to this group of drugs may also result from excessive plasma levels (which may be due to overdosage, unintentional intravascular injection, or slow metabolic degradation), injection technique, volume of injection, or hypersensitivity or they may be idiosyncratic. The most common adverse reactions (incidence >2%) are headache and pain ( 6.1 ). To report SUSPECTED","confidence":0.95,"sourceType":"fda_label","retrievedAt":"2026-04-19T23:37:08.586250+00:00"},"safety.contraindications":{"url":"","method":"ai_extraction","source":"FDA Label + AI","aiModel":"featherless","rawText":"","confidence":0.95,"sourceType":"fda_label","retrievedAt":"2026-04-19T23:37:11.865474+00:00"},"regulatory.fda_application":{"url":"","method":"deterministic","source":"FDA Label","rawText":"NDA022466","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-19T23:36:13.051157+00:00"}},"allNames":"septocaine","offLabel":[],"synonyms":["articaine","carticaine","articaine hydrochloride","articaine HCl"],"timeline":[{"date":"2000-04-03","type":"positive","source":"DrugCentral","milestone":"FDA approval"},{"date":"2028-08-15","type":"negative","source":"FDA Orange Book","milestone":"New Product exclusivity expires"}],"aiSummary":"Articaine, marketed as Septocaine, is a local anesthetic currently in use for infiltrative or conductive anesthesia, holding a significant position in the dental and surgical markets. Its key strength lies in its mechanism of action, which effectively blocks nerve impulses by increasing the threshold for electrical excitation and slowing nerve impulse propagation, offering rapid onset and a favorable safety profile. The primary risk to Articaine's market position is the expiration of its key composition patent in 2028, which could lead to increased competition from generics.","brandName":"Septocaine","ecosystem":[{"indication":"Administration of Local Anesthetic Nerve Block","otherDrugs":[{"name":"epinephrine","slug":"epinephrine","company":""},{"name":"mepivacaine","slug":"mepivacaine","company":"Eastman Kodak"}],"globalPrevalence":null},{"indication":"Local anesthesia, by infiltration","otherDrugs":[{"name":"epinephrine","slug":"epinephrine","company":""},{"name":"mepivacaine","slug":"mepivacaine","company":"Eastman Kodak"}],"globalPrevalence":null}],"mechanism":{"target":"Sodium channel alpha subunits; brain (Types I, II, III)","novelty":"Follow-on","targets":[{"gene":"SCN1A","source":"DrugCentral","target":"Sodium channel alpha subunits; brain (Types I, II, III)","protein":"Sodium channel protein type 1 subunit alpha"},{"gene":"SCN2A","source":"DrugCentral","target":"Sodium channel alpha subunits; brain (Types I, II, III)","protein":"Sodium channel protein type 2 subunit alpha"},{"gene":"SCN3A","source":"DrugCentral","target":"Sodium channel alpha subunits; brain (Types I, II, III)","protein":"Sodium channel protein type 3 subunit alpha"}],"modality":"Small molecule","drugClass":"Amide Local Anesthetic","explanation":"Articaine HCl works as a local anesthetic by interfering with the normal function of nerves. It increases the threshold needed to trigger a nerve impulse, slows down the speed at which the impulse travels, and reduces the speed at which the nerve cell can generate an impulse. This leads to a loss of sensation in the area where it is applied.","oneSentence":"Articaine HCl blocks nerve impulses by increasing the threshold for electrical excitation, slowing nerve impulse propagation, and reducing the rate of rise of the action potential.","technicalDetail":"Local anesthetics like articaine HCl block the generation and conduction of nerve impulses by increasing the threshold for electrical excitation in the nerve, slowing the propagation of the nerve impulse, and reducing the rate of rise of the action potential. The progression of anesthesia is related to the diameter, myelination, and conduction velocity of the affected nerve fibers.","_target_confidence":0.5},"commercial":{"launchDate":"2000","_launchSource":"DrugCentral (FDA 2000-04-03, )"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/3070","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=ARTICAINE","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=ARTICAINE","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files","fields":["patents","exclusivity","genericManufacturers"],"source":"FDA Orange Book"}],"_enrichedAt":"2026-03-30T08:50:09.704937","_validation":{"fieldsValidated":4,"lastValidatedAt":"2026-04-19T23:38:28.536096+00:00","fieldsConflicting":1,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"bupivacaine","drugSlug":"bupivacaine","fdaApproval":"1972-10-03","patentExpiry":"Mar 17, 2042","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"lidocaine","drugSlug":"lidocaine","fdaApproval":"1948-11-19","patentExpiry":"May 10, 2031","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"mepivacaine","drugSlug":"mepivacaine","fdaApproval":"1960-01-06","genericCount":9,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"prilocaine","drugSlug":"prilocaine","fdaApproval":"1965-11-18","genericCount":1,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"cinchocaine","drugSlug":"cinchocaine","fdaApproval":"","relationship":"same-class"},{"drugName":"etidocaine","drugSlug":"etidocaine","fdaApproval":"1976-08-30","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"ropivacaine","drugSlug":"ropivacaine","fdaApproval":"1996-09-24","patentExpiry":"Nov 28, 2026","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"levobupivacaine","drugSlug":"levobupivacaine","fdaApproval":"1999-08-05","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"meloxicam","drugSlug":"meloxicam","fdaApproval":"2000-04-13","patentExpiry":"May 26, 2030","patentStatus":"Patent protected","relationship":"same-class"}],"exclusivity":[{"code":"NP","date":"Aug 15, 2028"}],"genericName":"articaine","indications":{"approved":[{"id":"articaine-local,-infiltrative,-or-conduc","name":"Local, Infiltrative, or Conductive Anesthesia","dosing":null,"approvals":[],"diseaseId":"","eligibility":"Adults and pediatric patients 4 years of age and older","pivotalTrial":null,"restrictions":[],"patientPopulation":"Adults and pediatric patients 4 years of age and older","diagnosticRequired":null,"brandNameForIndication":"Septocaine"}],"offLabel":[],"pipeline":[]},"_fixedFields":["pubmed(802)"],"currentOwner":"Am Genomics","drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"bupivacaine","brandName":"bupivacaine","genericName":"bupivacaine","approvalYear":"1972","relationship":"same-class"},{"drugId":"lidocaine","brandName":"lidocaine","genericName":"lidocaine","approvalYear":"1948","relationship":"same-class"},{"drugId":"mepivacaine","brandName":"mepivacaine","genericName":"mepivacaine","approvalYear":"1960","relationship":"same-class"},{"drugId":"prilocaine","brandName":"prilocaine","genericName":"prilocaine","approvalYear":"1965","relationship":"same-class"},{"drugId":"cinchocaine","brandName":"cinchocaine","genericName":"cinchocaine","approvalYear":"","relationship":"same-class"},{"drugId":"etidocaine","brandName":"etidocaine","genericName":"etidocaine","approvalYear":"1976","relationship":"same-class"},{"drugId":"ropivacaine","brandName":"ropivacaine","genericName":"ropivacaine","approvalYear":"1996","relationship":"same-class"},{"drugId":"levobupivacaine","brandName":"levobupivacaine","genericName":"levobupivacaine","approvalYear":"1999","relationship":"same-class"},{"drugId":"meloxicam","brandName":"meloxicam","genericName":"meloxicam","approvalYear":"2000","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT07066306","phase":"NA","title":"Effects of Local Ketamine in Orthognathic Procedures","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bezmialem Vakif University","startDate":"2025-06-21","conditions":["Dentofacial Deformities","Analgesia","Vomiting, Postoperative","Nausea, Postoperative"],"enrollment":40,"completionDate":"2026-08-25"},{"nctId":"NCT06749158","phase":"NA","title":"Radiographic and Histological Assessment of GBR Using DBB Compared to Spontaneous Bone Regeneration of Maxillary Defects , Resulted From Enucleation of Intra-bony Cystic Lesions","status":"COMPLETED","sponsor":"Cairo University","startDate":"2024-12-30","conditions":["Maxillary Cyst"],"enrollment":44,"completionDate":"2026-02-01"},{"nctId":"NCT06017791","phase":"NA","title":"Management of Excess Gingival Display Using Tunnel Technique With 3D Designed PEEK Shell: A Case Series","status":"COMPLETED","sponsor":"Cairo University","startDate":"2023-11-08","conditions":["Excessive Gingival Display"],"enrollment":10,"completionDate":"2026-01-07"},{"nctId":"NCT07366788","phase":"NA","title":"Clinical Outcomes of Mandibular Primary Molar Extraction Using Physics Forceps in Children","status":"COMPLETED","sponsor":"Damascus University","startDate":"2025-05-21","conditions":["Dental Anxiety","Dental Pain","Dental Extraction","Primary Molar Tooth"],"enrollment":80,"completionDate":"2025-12-31"},{"nctId":"NCT07467369","phase":"NA","title":"Magnetic Mallet and Piezotome in Atrophic Anterior Maxillary Ridge Expansion With Simultaneous Bone Graft and Implant Placement (","status":"COMPLETED","sponsor":"Alexandria University","startDate":"2025-01-19","conditions":["Alveolar Bone Loss"],"enrollment":20,"completionDate":"2025-07-21"},{"nctId":"NCT07409896","phase":"NA","title":"Comparison of Anesthetic Efficacy OF 2% Lidocaine Inferior Alveolar Nerve (IANB) Block Versus Primary Buccal Infilteration With 4% Articaine in Symptomatic Irreversible Pulpitis(SIP) IN Mandibular First Molars","status":"NOT_YET_RECRUITING","sponsor":"Armed Forces Institute of Dentistry, Pakistan","startDate":"2026-02-01","conditions":["Anesthetic Efficacy"],"enrollment":330,"completionDate":"2027-02-01"},{"nctId":"NCT07384988","phase":"PHASE2","title":"The Impact of Nitrous Oxide Sedation on Dental Fear and Anxiety Scores in Children Aged 6-10 Years","status":"COMPLETED","sponsor":"Shaoxing Maternity and Child Health Care Hospital","startDate":"2024-01-15","conditions":["Dental Anxiety"],"enrollment":60,"completionDate":"2024-09-08"},{"nctId":"NCT07364253","phase":"NA","title":"'Propolis Versus Chlorhexidine Gluconate on Wound Healing After Third Molar Surgery: a Randomized Controlled Trial'","status":"COMPLETED","sponsor":"Ataturk University","startDate":"2021-01-05","conditions":["Third Molar Surgery","Post Operative Analgesia"],"enrollment":52,"completionDate":"2022-01-07"},{"nctId":"NCT07374354","phase":"NA","title":"Preemptive Analgesia for Pain and Anxiety Control in Children With MIH","status":"RECRUITING","sponsor":"October University for Modern Sciences and Arts","startDate":"2026-02","conditions":["Pain and Anxiety in Children With MIH"],"enrollment":46,"completionDate":"2026-02-01"},{"nctId":"NCT07011303","phase":"NA","title":"Investigation of the Effect of Horizontal Platelet Rich Fibrin Placed in Tooth Extraction Sockets on Bone Formation","status":"ENROLLING_BY_INVITATION","sponsor":"Tokat Gaziosmanpasa University","startDate":"2024-06-01","conditions":["Tooth Loss","Dental Implant Failed","Alveolar Bone Loss"],"enrollment":30,"completionDate":"2026-04-01"},{"nctId":"NCT06244797","phase":"NA","title":"Investigation of the Effects of H-PRF on the Period After Impacted Third Molar Tooth Extraction","status":"COMPLETED","sponsor":"esengul sen","startDate":"2023-12-18","conditions":["Impacted Third Molar Tooth"],"enrollment":75,"completionDate":"2024-05-14"},{"nctId":"NCT07352813","phase":"NA","title":"Intraosseous vs Infiltration Anesthesia in Molar-Incisor Hypomineralization (MIH) Children","status":"RECRUITING","sponsor":"Ankara Yildirim Beyazıt University","startDate":"2025-11-07","conditions":["Molar Incisor Hypomineralization","Hypersensitivity"],"enrollment":30,"completionDate":"2026-12-01"},{"nctId":"NCT07326241","phase":"NA","title":"Effects of Silver Diamine Fluoride and Intraoral Cryotherapy on Local Anesthesia in MIH-Affected Molars","status":"NOT_YET_RECRUITING","sponsor":"Çanakkale Onsekiz Mart University","startDate":"2026-02-01","conditions":["MIH","Molar-Incisor Hypomineralization","Caries Assessment"],"enrollment":75,"completionDate":"2026-04-01"},{"nctId":"NCT07318311","phase":"NA","title":"Comparative Evaluation of the Effect of pH Adjustment of the Solution of Articaine With Epinephrine on the Efficacy of Jet Anesthesia","status":"COMPLETED","sponsor":"Aristotle University Of Thessaloniki","startDate":"2022-08-01","conditions":["Comparative Evaluation of the Effect of pH Adjustment of the Solution of Articaine With Epinephrine on the Efficacy of Jet Anesthesia"],"enrollment":45,"completionDate":"2022-11-07"},{"nctId":"NCT07268456","phase":"","title":"Treatment of Complex Ridge Defects With Custom Meshes","status":"COMPLETED","sponsor":"TC Erciyes University","startDate":"2025-02-06","conditions":["Bone Defects"],"enrollment":15,"completionDate":"2025-08-10"},{"nctId":"NCT06852066","phase":"NA","title":"Comparison of Computer-Assisted and Conventional Local Anesthesia Methods in Mandibular Impacted Third Molar Surgery","status":"COMPLETED","sponsor":"Afyonkarahisar Health Sciences University","startDate":"2025-03-01","conditions":["Molar, Third","Surgery, Oral","Anxiety","Local Anesthesia","Hemodynamic Changes","Comparison of the Efficacy","Computer Assisted Local Anesthesia"],"enrollment":40,"completionDate":"2025-08-01"},{"nctId":"NCT07269171","phase":"NA","title":"The Effect of Supplementary Foods Containing Trypsin, Chymotrypsin and Serratia Peptidase on Healing After Impacted Wisdom Tooth Surgery","status":"NOT_YET_RECRUITING","sponsor":"Saglik Bilimleri Universitesi","startDate":"2025-12-01","conditions":["Oral Health Care"],"enrollment":15,"completionDate":"2026-03-10"},{"nctId":"NCT07233590","phase":"NA","title":"The Effect of Apical Patency on Postoperative Pain Following Root Canal Treatment","status":"COMPLETED","sponsor":"Cukurova University","startDate":"2024-10-05","conditions":["Postoperative Pain After Endodontic Treatment"],"enrollment":72,"completionDate":"2025-02-10"},{"nctId":"NCT06927726","phase":"NA","title":"Assessment of Anesthetic Efficacy and Hemodynamic Stability of Two LA Drugs for Hypertensive Patients","status":"ENROLLING_BY_INVITATION","sponsor":"Tanta University","startDate":"2025-01-10","conditions":["Hypertension"],"enrollment":60,"completionDate":"2025-12-10"},{"nctId":"NCT07231614","phase":"PHASE4","title":"Anesthetic Effectiveness of Lidocaine Versus Articaine in Dentistry","status":"NOT_YET_RECRUITING","sponsor":"Universidad Austral de Chile","startDate":"2025-12-20","conditions":["Dental Pain"],"enrollment":100,"completionDate":"2026-01-25"},{"nctId":"NCT07108439","phase":"NA","title":"Usefulness of Intraosseous Anesthesia for Permanent Tooth Extraction Under GA in Pediatric Dental Treatment","status":"RECRUITING","sponsor":"University Hospital, Ghent","startDate":"2025-08-14","conditions":["No Condition, Assessment of Healthy Volunteers"],"enrollment":80,"completionDate":"2027-05-06"},{"nctId":"NCT06655766","phase":"NA","title":"Socket Preservation Using Socket-plug Technique With Alloplastic Putty Bone Versus Ice Cream Cone Technique in Extraction Socket With Buccal Dehiscence.","status":"NOT_YET_RECRUITING","sponsor":"Cairo University","startDate":"2025-10-30","conditions":["Socket Preservation"],"enrollment":30,"completionDate":"2026-02-01"},{"nctId":"NCT06914518","phase":"NA","title":"Polynucleotide and Hyaluronic Acid-based Gel as Adjunctive Therapy to Non- Surgical Treatment of Intraosseous Peri-implant Defect. A Randomized Clinical Trial","status":"NOT_YET_RECRUITING","sponsor":"Universitat Internacional de Catalunya","startDate":"2025-09-20","conditions":["Peri-implantitis"],"enrollment":32,"completionDate":"2026-06-01"},{"nctId":"NCT07184879","phase":"NA","title":"Comparison of Five Anesthetic Delivery Systems for Palatal Infiltration","status":"COMPLETED","sponsor":"Sercan Küçükkurt","startDate":"2023-09-01","conditions":["Dental Anxiety","Pain","Dental","Palatal Anesthesia"],"enrollment":200,"completionDate":"2025-03-01"},{"nctId":"NCT07177495","phase":"NA","title":"Radiographic and Histomorphometric Assessment for Maxillary Sinus Floor Elevation and Augmentation Using A Mixture of 1:1 Autogenous Bone With Deproteinized Bovine Bone Particulate Versus Deproteinized Bovine Bone Particulate","status":"RECRUITING","sponsor":"Cairo University","startDate":"2025-04-10","conditions":["Maxillary Sinus Lifting"],"enrollment":26,"completionDate":"2026-03-10"},{"nctId":"NCT07156487","phase":"NA","title":"Pain and Anxiety in Pediatric Dentistry: Computer-Controlled vs. Traditional Anesthesia","status":"NOT_YET_RECRUITING","sponsor":"Dicle University","startDate":"2025-10","conditions":["Traditional Local Anesthesia","Computer-controlled Electronic Anesthesia","Dental Anxiety","Anxiety in Children"],"enrollment":84,"completionDate":"2026-03"},{"nctId":"NCT07156032","phase":"NA","title":"Effect of Starpen Injection Device Versus Conventional Syringe During Anesthesia and Extraction of Primary Molars","status":"NOT_YET_RECRUITING","sponsor":"Cairo University","startDate":"2026-01","conditions":["Pain Perception of the New Device"],"enrollment":38,"completionDate":"2026-10"},{"nctId":"NCT07145879","phase":"NA","title":"Comparison of Postoperative Effects of Articaine and Lidocaine in Mucogingival Surgery","status":"COMPLETED","sponsor":"Pamukkale University","startDate":"2025-01-01","conditions":["Local Analgesia Via Infiltration","Wound Heal","Pain, Postoperative","Hemorrhage"],"enrollment":43,"completionDate":"2025-07-30"},{"nctId":"NCT07124273","phase":"NA","title":"Effect of Dental Anxiety on Mandibular Anesthesia Success","status":"COMPLETED","sponsor":"Kutahya Health Sciences University","startDate":"2023-12-15","conditions":["Dental Anxiety","Symptomatic Irreversible Pulpitis"],"enrollment":52,"completionDate":"2024-12-15"},{"nctId":"NCT06461143","phase":"NA","title":"Intraosseous Local Anesthesia System in Children With Molar Incisor Hypomineralization","status":"SUSPENDED","sponsor":"Istanbul University","startDate":"2024-08-21","conditions":["Molar Incisor Hypomineralization","Hypersensitivity","Composite Restoration"],"enrollment":80,"completionDate":"2026-05-24"},{"nctId":"NCT07095530","phase":"NA","title":"Horizontal Ridge Augmentation Using Polyvinylidene Fluoride Versus Titanium Mesh Membranes","status":"COMPLETED","sponsor":"Minia University","startDate":"2024-06-01","conditions":["Horizontal Alveolar Bone Loss"],"enrollment":42,"completionDate":"2025-01-20"},{"nctId":"NCT07087028","phase":"NA","title":"Digital vs. Conventional Anesthesia for Primary Tooth Extractions in Pediatric Patients","status":"COMPLETED","sponsor":"Ege University","startDate":"2020-01-20","conditions":["Pain Management","Dental Anxiety","Pediatric Dentistry","Dental Anesthesia"],"enrollment":20,"completionDate":"2022-01-02"},{"nctId":"NCT07077694","phase":"NA","title":"Artificial Intelligence to Detect Missed Root Canals in Previously Treated Lower Back Teeth Using 3D Dental Imaging (CBCT)","status":"ENROLLING_BY_INVITATION","sponsor":"Future University in Egypt","startDate":"2024-12-25","conditions":["Presence of Missed Canals","Morphological Variation"],"enrollment":3,"completionDate":"2025-10-29"},{"nctId":"NCT07068750","phase":"NA","title":"Evaluation of Implant Site Preparation With Three Different Drilling Systems in Posterior Maxilla (Randomized Controlled Clinical Trial)","status":"COMPLETED","sponsor":"ALZAHRANI,MOHAMMED AHMED Y","startDate":"2023-08-16","conditions":["Evaluation of Implant Site Preparation With Three Different Drilling Systems in Posterior Maxilla"],"enrollment":30,"completionDate":"2025-06-03"},{"nctId":"NCT07056101","phase":"NA","title":"\"Study of Pain Perception Using Computer-Controlled Versus Conventional Local Anaesthesia in Children Undergoing Molar Extraction","status":"NOT_YET_RECRUITING","sponsor":"Tarek MHD kher al saka amini","startDate":"2025-07-01","conditions":["Dental Phobia","Dental Anxiety","Dental Anesthesia","Dental Anesthesia Efficacy"],"enrollment":76,"completionDate":"2025-10-31"},{"nctId":"NCT07048834","phase":"PHASE2","title":"Comparison of the Effectiveness of Articaine Local Infusion and Lidocaine Nerve Block in Lower Posterior Tooth Extraction.","status":"COMPLETED","sponsor":"Amjed Fouad Hussein","startDate":"2021-03-15","conditions":["Anesthesia"],"enrollment":60,"completionDate":"2022-05-17"},{"nctId":"NCT07056998","phase":"NA","title":"On Previously Root Canal-treated Patients Using an AI Program, Detect the Accuracy of it in the Detection of Root Canal Obturation Quality on CBCT Compared With Conventional PA Radiography, e.g., Voids, Length of Obturation, and Density, and Then do Retreatment if Any Failure is Recorded.","status":"ENROLLING_BY_INVITATION","sponsor":"Tala Ghassan Hassan Odeh","startDate":"2025-04-01","conditions":["Root Canal Treatment"],"enrollment":3,"completionDate":"2025-10-30"},{"nctId":"NCT07019480","phase":"","title":"Influence of Implant Insertion Torque on Post-Surgical Marginal Bone Stability","status":"ACTIVE_NOT_RECRUITING","sponsor":"International Piezosurgery Academy","startDate":"2025-01-01","conditions":["Edentulous Alveolar Ridge"],"enrollment":150,"completionDate":"2035-12-31"},{"nctId":"NCT07018115","phase":"NA","title":"Anxiety and Hemodynamic Changes in Third Molar Extraction After Patient Education","status":"COMPLETED","sponsor":"Ummugulsum Coskun","startDate":"2015-06-01","conditions":["Dental Anxiety","Hemodynamic","Molar, Third","Tooth Extraction","Tooth Impacted"],"enrollment":97,"completionDate":"2016-12-10"},{"nctId":"NCT06314425","phase":"NA","title":"Zirconia Implants: Practice-based Evidence","status":"ACTIVE_NOT_RECRUITING","sponsor":"Swiss Dental Solutions","startDate":"2025-01-03","conditions":["Dental Implants","Ceramic Implant"],"enrollment":100,"completionDate":"2026-12-31"},{"nctId":"NCT05739682","phase":"NA","title":"Pain and Microbial Reduction of Antimicrobial Corticosteroid Mixture Versus Cryotherapy in Necrotic Teeth","status":"COMPLETED","sponsor":"Cairo University","startDate":"2024-07-01","conditions":["Dental Pulp Necrosis"],"enrollment":28,"completionDate":"2025-02-09"},{"nctId":"NCT06630819","phase":"NA","title":"Buccal Infiltration of Different Volumes of Articaine for Extraction.","status":"RECRUITING","sponsor":"Qassim University","startDate":"2024-11-24","conditions":["Buccal Infiltration","Articaine","Anesthesia"],"enrollment":114,"completionDate":"2026-05-02"},{"nctId":"NCT06992193","phase":"NA","title":"Effectiveness of Digital Anesthesia Versus Conventional Techniques in Reducing Pain and Anxiety in Children","status":"COMPLETED","sponsor":"Ege University","startDate":"2025-01-08","conditions":["Pain in Pediatric Dentistry","Dental Anxiety"],"enrollment":79,"completionDate":"2025-04-01"},{"nctId":"NCT06606587","phase":"NA","title":"Effectiveness of the Comfort-In Needle Free Injection System During Palatal Infiltrative Anesthesia","status":"COMPLETED","sponsor":"Necmettin Erbakan University","startDate":"2023-01-01","conditions":["Physiological Effects of Drugs","Anesthetics"],"enrollment":56,"completionDate":"2023-12-01"},{"nctId":"NCT06980363","phase":"PHASE1","title":"Hyaluronidase Enzymes and Local Anesthesia","status":"NOT_YET_RECRUITING","sponsor":"Fayoum University","startDate":"2025-06-01","conditions":["Local Infiltration"],"enrollment":20,"completionDate":"2025-08-27"},{"nctId":"NCT06047366","phase":"PHASE4","title":"Combination of Buffered Anesthetic to Treat Mandibular Molars","status":"TERMINATED","sponsor":"Indiana University","startDate":"2023-12-05","conditions":["Symptomatic Irreversible Pulpitis"],"enrollment":40,"completionDate":"2024-05-15"},{"nctId":"NCT05728151","phase":"NA","title":"Comparing General Anesthesia With Single Injection Peribulbar Block With 3 Different Drugs","status":"COMPLETED","sponsor":"Research Institute of Ophthalmology, Egypt","startDate":"2022-02-22","conditions":["Pediatric Squint Surgeries"],"enrollment":55,"completionDate":"2024-04-18"},{"nctId":"NCT06920485","phase":"NA","title":"Effect of Hypochlorous Acid-containing Mouthwash on Healing After Impacted Wisdom Tooth Surgery","status":"ENROLLING_BY_INVITATION","sponsor":"Saglik Bilimleri Universitesi","startDate":"2025-05-01","conditions":["Oral Health"],"enrollment":96,"completionDate":"2027-04-01"},{"nctId":"NCT06785480","phase":"NA","title":"Evaluation of Computer-controlled Local Anesthesia in Children - a Clinical Trial","status":"COMPLETED","sponsor":"University Hospital, Ghent","startDate":"2022-10-19","conditions":["Local Anesthesia Injection Pain"],"enrollment":47,"completionDate":"2025-01-31"},{"nctId":"NCT05460988","phase":"NA","title":"\"Re-instrumentation vs Flap Surgery\"","status":"COMPLETED","sponsor":"University of Florence","startDate":"2022-08-11","conditions":["Periodontal Pocket","Periodontitis"],"enrollment":46,"completionDate":"2024-07-11"},{"nctId":"NCT06766981","phase":"NA","title":"Infiltration Anesthesia vs. Block Anesthesia","status":"COMPLETED","sponsor":"Sinan A. Shwailiya","startDate":"2025-01-10","conditions":["Tooth Extraction"],"enrollment":100,"completionDate":"2025-03-01"},{"nctId":"NCT06886243","phase":"NA","title":"Menstrual Cycle Effects on Postoperative Sensitivity and Rebound Pain in Composite Restorations","status":"COMPLETED","sponsor":"Firat University","startDate":"2022-08-01","conditions":["Postoperative Sensitivity","Rebound Pain","Menstrual Cycle","Composite Restorations"],"enrollment":35,"completionDate":"2023-06-30"},{"nctId":"NCT06892873","phase":"NA","title":"Clinical Evaluation and Comparison of Pain Acceptance of Different Types of Injection Systems","status":"COMPLETED","sponsor":"Necmettin Erbakan University","startDate":"2024-01-22","conditions":["Dental Anesthesia"],"enrollment":76,"completionDate":"2024-09-06"},{"nctId":"NCT06865976","phase":"","title":"Genomic and Proteomic Analyses of Apoptosis Mechanisms in Diseased Peri-implant Tissue","status":"COMPLETED","sponsor":"Sakarya University","startDate":"2021-03-01","conditions":["Apoptosis","Apoptosis Regulatory Proteins","Proteases","Peri-Implantitis and Peri-implant Mucositis"],"enrollment":72,"completionDate":"2024-09-01"},{"nctId":"NCT06862570","phase":"PHASE2","title":"Assessment of Local Anaesthesia Effectiveness in Symptomatic Irreversible Pulpitis","status":"COMPLETED","sponsor":"28 Military Dental Centre Lahore","startDate":"2022-12-19","conditions":["Symptomatic Irreversible Pulpitis"],"enrollment":123,"completionDate":"2023-05-19"},{"nctId":"NCT06816277","phase":"NA","title":"Application of Local Melatonin in Peri-implantitis","status":"COMPLETED","sponsor":"Universidad Complutense de Madrid","startDate":"2020-09-01","conditions":["Periimplantitis"],"enrollment":30,"completionDate":"2023-07-15"},{"nctId":"NCT06806566","phase":"NA","title":"Assessment of a Carvacrol-loaded Absorbable Gelatin Sponge Used As a Palatal Dressing Following Free Gingival Graft Harvesting: a Randomized Clinical Study","status":"RECRUITING","sponsor":"British University In Egypt","startDate":"2024-02-01","conditions":["Palatal Wound"],"enrollment":30,"completionDate":"2025-05-01"},{"nctId":"NCT05839548","phase":"PHASE3","title":"Articaine Efficacy and Safety for 3 Years Old Children","status":"ACTIVE_NOT_RECRUITING","sponsor":"Qassim Health Cluster","startDate":"2023-07-01","conditions":["Dental Caries in Children","Dental Diseases","Pulp Disease, Dental","Behavior, Child"],"enrollment":200,"completionDate":"2025-05-31"},{"nctId":"NCT06641232","phase":"NA","title":"Comparison of Anesthetic Efficacy and Safety Between Nerve Block and Infiltrative Technique for Mandibular Posterior Implant Placement.","status":"RECRUITING","sponsor":"University of Barcelona","startDate":"2024-11-05","conditions":["Dental Implants","Local Anesthesia"],"enrollment":42,"completionDate":"2026-06"},{"nctId":"NCT06726837","phase":"NA","title":"Effect of Different Root Canal Sealers on Postoperative Pain","status":"NOT_YET_RECRUITING","sponsor":"Dicle University","startDate":"2025-01-01","conditions":["Postoperative Dental Pain","Root Canal Obturation","Warm Vertical Compaction","Root Canal Sealers","Visual Analog Scale"],"enrollment":72,"completionDate":"2025-11-01"},{"nctId":"NCT05443009","phase":"PHASE4","title":"Self-Reported Pain in Children Submitted to Single Infiltration of Articaine During Primary Molar Extraction","status":"COMPLETED","sponsor":"Universidade Federal de Santa Catarina","startDate":"2022-06-30","conditions":["Dental Pain","Anesthesia, Local"],"enrollment":76,"completionDate":"2024-11-21"},{"nctId":"NCT06679660","phase":"NA","title":"Comparative Assessment of Mental/Incisive and Inferior Alveolar Nerve Block Anesthesia in Root Canal Treatment of Mandibular Premolars","status":"COMPLETED","sponsor":"Cukurova University","startDate":"2023-02-20","conditions":["Mandibular Nerve","Mandibular Nerve Blocks","Premolars","Mental Nerve Block"],"enrollment":120,"completionDate":"2024-09-15"},{"nctId":"NCT06644950","phase":"NA","title":"Efficacy and Safety of Administration of Different Doses of 4% Articaine.","status":"COMPLETED","sponsor":"University of Barcelona","startDate":"2023-05-25","conditions":["Tooth Extraction Status Nos","Anesthesia, Local"],"enrollment":110,"completionDate":"2024-10-02"},{"nctId":"NCT06643468","phase":"NA","title":"Effectiveness of ALB-PRF With Two Types of Bone Grafts With Putty Form Around Immediate Dental Implants.","status":"ENROLLING_BY_INVITATION","sponsor":"Mansoura University","startDate":"2024-08-14","conditions":["Dental Implants","Immediate Implant Soft Tissue Healing","Immediate Implant With Bone Graft"],"enrollment":60,"completionDate":"2025-06-01"},{"nctId":"NCT04104789","phase":"PHASE2","title":"Kovanaze Vs. Articaine in Achieving Pulpal Anesthesia of Maxillary Teeth - General","status":"WITHDRAWN","sponsor":"Virginia Commonwealth University","startDate":"2020-09","conditions":["Caries,Dental","Apical Periodontitis"],"enrollment":0,"completionDate":"2021-10"},{"nctId":"NCT05840913","phase":"PHASE2","title":"Different Volumes of Articaine for Inferior Alveolar Nerve Block in Irreversible Pulpitis","status":"COMPLETED","sponsor":"Armed Forces Institute of Dentistry, Pakistan","startDate":"2023-12-01","conditions":["Drug Effect","Pulpitis - Irreversible"],"enrollment":78,"completionDate":"2024-07-31"},{"nctId":"NCT04829344","phase":"PHASE3","title":"A Study of the Safety and Anesthetic Effect of AG-920 Topical Ophthalmic Solution","status":"COMPLETED","sponsor":"American Genomics, LLC","startDate":"2021-03-30","conditions":["Anesthesia, Local"],"enrollment":120,"completionDate":"2021-05-10"},{"nctId":"NCT05501860","phase":"PHASE3","title":"A Safety Study of of AG-920 Sterile Topical Ophthalmic Solution","status":"COMPLETED","sponsor":"American Genomics, LLC","startDate":"2022-07-30","conditions":["Anesthesia, Local"],"enrollment":249,"completionDate":"2022-12-07"},{"nctId":"NCT04403503","phase":"NA","title":"The Influence of Tissue Adhesive to Palatal Donor Site Healing.","status":"COMPLETED","sponsor":"Hacettepe University","startDate":"2018-07-01","conditions":["Donor Site Complication"],"enrollment":42,"completionDate":"2019-03-01"},{"nctId":"NCT06620718","phase":"NA","title":"Evaluation of Root Migration Distance After Coronectomy of Impacted Third Molars","status":"COMPLETED","sponsor":"Mustafa Kemal University","startDate":"2021-01-01","conditions":["Impacted Tooth With Abnormal Positioning"],"enrollment":73,"completionDate":"2022-12-30"},{"nctId":"NCT06583226","phase":"NA","title":"The Effect of Two Different Approaches on Palatal Donor Site","status":"COMPLETED","sponsor":"Medipol University","startDate":"2023-10-10","conditions":["Wound Heal"],"enrollment":50,"completionDate":"2024-05-20"},{"nctId":"NCT06564987","phase":"PHASE1","title":"Risk of Nerve Damage After Administration of Local Anesthesia","status":"RECRUITING","sponsor":"Cleveland Dental Institute","startDate":"2024-01-01","conditions":["Inferior Alveolar Nerve Injuries"],"enrollment":80,"completionDate":"2025-03-31"},{"nctId":"NCT06083259","phase":"NA","title":"Cyanoacrylate With or Without Suture?","status":"COMPLETED","sponsor":"Hacettepe University","startDate":"2023-12-05","conditions":["Wound Heal"],"enrollment":37,"completionDate":"2024-08-16"},{"nctId":"NCT06552715","phase":"PHASE1","title":"Pilot Study on the Effectiveness of a Flexible Hydroxyapatite-Based Composite for Jaw Bone Regeneration","status":"NOT_YET_RECRUITING","sponsor":"University of Bologna","startDate":"2024-09","conditions":["Bone Atrophy","Edentulism","Bone Regeneration"],"enrollment":20,"completionDate":"2025-09"},{"nctId":"NCT06548516","phase":"NA","title":"Maxillary Labial Frenectomy: Diode Lasers Versus Surgical Scalpel","status":"RECRUITING","sponsor":"Necmettin Erbakan University","startDate":"2024-04-01","conditions":["High Frenum Attachment"],"enrollment":43,"completionDate":"2024-09"},{"nctId":"NCT06500871","phase":"EARLY_PHASE1","title":"Evaluation of the Effect of Intra-ligamentary Injection of Diclofenac Potassium Versus Articaine on Anaesthetic Efficacy in Mandibular Molars With Symptomatic Irreversible Pulpitis.","status":"NOT_YET_RECRUITING","sponsor":"Cairo University","startDate":"2024-08","conditions":["Teeth With Acute Irreverseble Pulpitis"],"enrollment":40,"completionDate":"2025-07"},{"nctId":"NCT06538233","phase":"PHASE2","title":"Pain After Buffered Vs Non Buffered Articaine","status":"RECRUITING","sponsor":"Cleveland Dental Institute","startDate":"2024-01-01","conditions":["Pain"],"enrollment":108,"completionDate":"2025-01-31"},{"nctId":"NCT06498180","phase":"NA","title":"Periodontal Initial Treatment Combined With Glucocorticoid Therapy for Erosive Oral Lichen Planus","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University","startDate":"2024-12-31","conditions":["Oral Lichen Planus","Periodontal Diseases"],"enrollment":29,"completionDate":"2028-03-31"},{"nctId":"NCT05841290","phase":"NA","title":"The Incidence of Postoperative Pain After Using Different Types of Sealers","status":"RECRUITING","sponsor":"British University In Egypt","startDate":"2022-08-01","conditions":["Post Operative Pain","Root Canal Sealers","Sillicon Based Sealers","Resin Based Sealers"],"enrollment":50,"completionDate":"2024-10"},{"nctId":"NCT06423859","phase":"NA","title":"Articaine Plus Dexmedetomidine in Supraclavicular Block","status":"RECRUITING","sponsor":"Benha University","startDate":"2024-02-01","conditions":["Post Operative Pain, Acute"],"enrollment":66,"completionDate":"2024-08-20"},{"nctId":"NCT06408792","phase":"NA","title":"To Evaluate Postoperative Pain and Quality of Life After Taking a Deephethelized Gingival Graft and Covering it With Different Treatments","status":"RECRUITING","sponsor":"Universidad Complutense de Madrid","startDate":"2024-04-02","conditions":["Pain, Postoperative","Quality of Life","Palate; Wound"],"enrollment":33,"completionDate":"2024-10-01"},{"nctId":"NCT04865848","phase":"NA","title":"Comparison of Articaine Mandibular Infiltration to Lidocaine Inferior Alveolar Nerve Block in Pediatric Patients","status":"TERMINATED","sponsor":"University of Illinois at Chicago","startDate":"2019-06-05","conditions":["Anesthesia"],"enrollment":42,"completionDate":"2022-05-05"},{"nctId":"NCT01912755","phase":"PHASE4","title":"Anesthetic Efficacy of Articaine and Lidocaine in Lower Molars With Irreversible Pulpits","status":"COMPLETED","sponsor":"University of Campinas, Brazil","startDate":"2010-02","conditions":["Irreversible Pulpitis","Pain"],"enrollment":50,"completionDate":"2011-01"},{"nctId":"NCT06357481","phase":"NA","title":"Evaluation of Postoperative Pain After Single Visit Retreatment of Symptomatic and Asymptomatic Teeth","status":"COMPLETED","sponsor":"Saglik Bilimleri Universitesi","startDate":"2023-01-26","conditions":["Post-operative Pain","Retreatment","Symptomatic Periapical Periodontitis","Endodontic Disease","Asymptomatic Periapical Periodontitis"],"enrollment":80,"completionDate":"2024-01-28"},{"nctId":"NCT06353815","phase":"NA","title":"Clinical Evaluation of Anaesthetic Efficacy of 4% Articaine Buccal Infiltration Versus Inferior Alveolar Nerve Block","status":"NOT_YET_RECRUITING","sponsor":"Cairo University","startDate":"2024-07","conditions":["Restorative Dental Treatment by Buccal Infiltration Anaesthesia"],"enrollment":44,"completionDate":"2025-06"},{"nctId":"NCT06009302","phase":"NA","title":"Analgesic Effects of Extraoral Ultrasound Block of Mandibular Nerve for the Extraction of Lower Third Molars","status":"COMPLETED","sponsor":"Varazdin General Hospital","startDate":"2023-09-01","conditions":["Molar","Impacted Teeth"],"enrollment":36,"completionDate":"2023-12-31"},{"nctId":"NCT06342869","phase":"NA","title":"Comparison of the Effects of Lidocaine and Articaine Used for Buccal Infiltration and Supplemental Palatinal Infiltration Anesthesia in Teeth With Irreversible Pulpitis","status":"COMPLETED","sponsor":"Akdeniz University","startDate":"2022-04-01","conditions":["Fist and Second Molars With ırreversible Pulpitis"],"enrollment":80,"completionDate":"2022-12-01"},{"nctId":"NCT06340022","phase":"NA","title":"Pain and Anxiety Levels of Sleeperone Electronic Anesthesia System in Pediatric Patients","status":"COMPLETED","sponsor":"Eskisehir Osmangazi University","startDate":"2023-03-13","conditions":["Dental Anxiety","Pain"],"enrollment":32,"completionDate":"2023-11-15"},{"nctId":"NCT05083975","phase":"NA","title":"Buzzy System Compared to Topical Anaesthesia During Infiltration Injection in Children.","status":"COMPLETED","sponsor":"Cairo University","startDate":"2022-07-23","conditions":["Local Anaesthesia"],"enrollment":70,"completionDate":"2023-05-06"},{"nctId":"NCT06309095","phase":"NA","title":"Investigation of the Effect of Low Torque and Speed on Post-Operative Pain After Root Canal Treatment","status":"NOT_YET_RECRUITING","sponsor":"Afyonkarahisar Health Sciences University","startDate":"2024-03-15","conditions":["Dental Pulp Necrosis"],"enrollment":80,"completionDate":"2024-04-15"},{"nctId":"NCT06280014","phase":"NA","title":"Evaluation of the Effects of Mefenamic Acid and Dexketoprofen on Postoperative Wisdom Dental Surgery","status":"COMPLETED","sponsor":"Yuzuncu Yil University","startDate":"2022-01-20","conditions":["Tooth, Impacted","Tooth Diseases"],"enrollment":30,"completionDate":"2023-09-25"},{"nctId":"NCT06220383","phase":"NA","title":"Evaluation of The Effect of Crowns Applied With Hall Technique on Occlusion","status":"COMPLETED","sponsor":"Izmir Katip Celebi University","startDate":"2022-10-05","conditions":["Child, Only","Quality of Life"],"enrollment":78,"completionDate":"2023-12-20"},{"nctId":"NCT06201949","phase":"NA","title":"Articaine Infiltration in Anesthetizing Mandibular Second Primary Molars","status":"COMPLETED","sponsor":"Hams Hamed Abdelrahman","startDate":"2023-03-16","conditions":["Anesthesia, Local"],"enrollment":52,"completionDate":"2023-06-30"},{"nctId":"NCT06161714","phase":"PHASE4","title":"The Effectiveness of Buccal Infiltration Only Using Articaine for Extraction of Mandibular Molar","status":"UNKNOWN","sponsor":"Riyadh Elm University","startDate":"2023-11-30","conditions":["Pain"],"enrollment":40,"completionDate":"2024-04-30"},{"nctId":"NCT06119139","phase":"NA","title":"Anesthetic Efficacy of 1.8 ml Versus 3.6 ml of 4% Articaine Buccal Infiltration","status":"UNKNOWN","sponsor":"Cairo University","startDate":"2023-12","conditions":["Symptomatic Irreversible Pulpitis"],"enrollment":70,"completionDate":"2025-06"},{"nctId":"NCT06112366","phase":"NA","title":"Comparison of Silk Suture and Tissue Adhesive for Wound Closure After Impacted Tooth","status":"COMPLETED","sponsor":"Yuzuncu Yil University","startDate":"2022-05-20","conditions":["Tooth, Impacted","Tooth Diseases"],"enrollment":30,"completionDate":"2023-07-25"},{"nctId":"NCT05325853","phase":"PHASE3","title":"A Study of Safety and the Local Anesthetic Effect of AG-920 Ophthalmic Solution in a Pediatric Population","status":"COMPLETED","sponsor":"American Genomics, LLC","startDate":"2022-04-06","conditions":["Anesthesia, Local"],"enrollment":61,"completionDate":"2022-05-27"},{"nctId":"NCT06067542","phase":"NA","title":"Effects of Chlorhexidine Toothpaste on Wound Healing After Impacted Tooth Extraction","status":"COMPLETED","sponsor":"Yuzuncu Yil University","startDate":"2020-03-04","conditions":["Tooth Impaction","Tooth Diseases"],"enrollment":22,"completionDate":"2022-12-01"},{"nctId":"NCT05381623","phase":"NA","title":"Harvest of Free Gingival Grafts With or Without the Application of Hemostatic Sutures","status":"COMPLETED","sponsor":"Universidad Complutense de Madrid","startDate":"2022-05-20","conditions":["Thin-gingiva","Mucogingival Deformity on Edentulous Ridge","Gingival Recession"],"enrollment":34,"completionDate":"2022-09-30"},{"nctId":"NCT05214664","phase":"NA","title":"Efficiency of a Guiding Device for Inferior Alveolar Nerve Block, EZ-Block®, Compared to a Conventional Freehand Administration.","status":"UNKNOWN","sponsor":"Elsan","startDate":"2023-09-08","conditions":["Tooth Avulsion"],"enrollment":210,"completionDate":"2024-12"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"route":"Submucosal","formulation":"Injection","formulations":[{"form":"INJECTION","route":"SUBMUCOSAL","productName":"Articaine HCl and Epinephrine"},{"form":"INJECTION","route":"SUBMUCOSAL","productName":"Orabloc"},{"form":"INJECTION, SOLUTION","route":"SUBCUTANEOUS","productName":"ARTICAINE"},{"form":"INJECTION, SOLUTION","route":"SUBCUTANEOUS","productName":"Articadent"},{"form":"INJECTION, SOLUTION","route":"SUBCUTANEOUS","productName":"Articaine Hydrochloride and Epinephrine"},{"form":"INJECTION, SOLUTION","route":"SUBCUTANEOUS","productName":"Septocaine and Epinephrine"},{"form":"INJECTION, SOLUTION","route":"SUBCUTANEOUS","productName":"Zorcaine"},{"form":"INJECTION, SOLUTION","route":"SUBMUCOSAL","productName":"Ultacan"},{"form":"INJECTION, SOLUTION","route":"SUBMUCOSAL","productName":"Ultacan Forte"},{"form":"INJECTION, SOLUTION","route":"SUBMUCOSAL","productName":"Articaine Hydrochloride and Epinephrine"}]},"_patentsChecked":true,"crossReferences":{"NUI":"N0000148787","MMSL":"14782","NDDF":"003780","UNII":"D3SQ406G9X","VUID":"4021368","CHEBI":"CHEBI:91834","VANDF":"4021368","INN_ID":"3193","RXNORM":"2117","UMLSCUI":"C1608295","chemblId":"CHEMBL1200819","ChEMBL_ID":"CHEMBL1093","KEGG_DRUG":"D02991","DRUGBANK_ID":"DB09009","PUBCHEM_CID":"32170","SNOMEDCT_US":"410851000","SECONDARY_CAS_RN":"23964-57-0","MESH_DESCRIPTOR_UI":"D002355"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[{"period":"present","companyName":"Am Genomics","relationship":"Current Owner"}],"pharmacokinetics":{"source":"DrugCentral","halfLife":"0.98 hours","clearance":"126.7 mL/min/kg","fractionUnbound":"0.46%","volumeOfDistribution":"7.7 L/kg"},"publicationCount":808,"therapeuticAreas":["Neuroscience"],"atcClassification":{"source":"DrugCentral","atcCode":"N01BB08","allCodes":["N01BB08","N01BB58"]},"biosimilarFilings":[],"recentPublications":[{"date":"2026 Mar 19","pmid":"41892791","title":"Association of 4% Articaine with Profound Inferior Alveolar Nerve Block Success in Third Molar Surgery Performed by Dental Students: A Three-Anesthetic Observational Study.","journal":"Dentistry journal"},{"date":"2026 Feb","pmid":"41756792","title":"A comparative clinical study to evaluate the efficacy of lignocaine 2% and articaine 4% for anesthesia of mandibular first molars with irreversible pulpitis.","journal":"Journal of conservative dentistry and endodontics"},{"date":"2026 Feb 9","pmid":"41752384","title":"Sorbent Strip Microextraction as a Practical Tool for Drug Screening: Application to Opioids and Local Anesthetics in Human Urine.","journal":"Molecules (Basel, Switzerland)"},{"date":"2026 Jan-Mar","pmid":"41710613","title":"Selection of the safest local anesthetic for dental treatment in medically compromised patients: A comprehensive review.","journal":"Saudi journal of anaesthesia"},{"date":"2026 Jan","pmid":"41624361","title":"Comparative Evaluation of Efficacy of Buccal Infiltration and Intraligamentary Injection with 4% Articaine in Primary Molars: In Vivo Study.","journal":"International journal of clinical pediatric dentistry"}],"companionDiagnostics":[],"genericManufacturers":0,"_genericFilersChecked":true,"genericManufacturerList":[],"status":"approved","companyName":"Am Genomics","companyId":"","modality":"Small molecule","firstApprovalDate":"2000","enrichmentLevel":4,"visitCount":0,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2006-03-30T00:00:00.000Z","mah":"DEPROCO","brand_name_local":null,"application_number":"NDA020971"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2014-03-10T00:00:00.000Z","mah":"PIERREL","brand_name_local":null,"application_number":"NDA022466"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2025-08-15T00:00:00.000Z","mah":"AM GENOMICS","brand_name_local":null,"application_number":"NDA218643"},{"country_code":"MX","regulator":"COFEPRIS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AR","regulator":"ANMAT","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TR","regulator":"TITCK","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IN","regulator":"CDSCO","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TH","regulator":"FDA-TH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"MY","regulator":"NPRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"PH","regulator":"FDA-PH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CO","regulator":"INVIMA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"ZA","regulator":"SAHPRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TW","regulator":"TFDA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"HK","regulator":"DH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"BR","regulator":"ANVISA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":2,"withResults":0},"validation":{"fieldsValidated":4,"lastValidatedAt":"2026-04-19T23:38:28.536096+00:00","fieldsConflicting":1,"overallConfidence":0.8},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}